# 1250 ESTUDIOS SOBRE REACCIONES Y DAÑOS ADVERSOS PRODUCTO DE LA VACUNA COVID-19

## Neurologicos:

Spectrum of neurological complications following COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8557950/

COVID-19 mRNA vaccination leading to CNS inflammation: a case series https://link.springer.com/article/10.1007/s00415-021-10780-7?fbclid=IwAR1WIozzELtGyD_DttkLNZFMcl3yW6iBW9C0v8uRyiYtTulzRvKVPE_xYko

A systematic review of cases of CNS demyelination following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34839149/

Spectrum of neuroimaging findings in post-covid-19 vaccination: a case series and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34842783/

Neurologic autoimmune diseases following vaccinations: https://pubmed.ncbi.nlm.nih.gov/34668274/

New-onset autoimmune phenomena post COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34957554/

Neurologic side effects of COVID-19 vaccinations: https://pubmed.ncbi.nlm.nih.gov/34750810/

Rebuttal about Functional Neurologic Disorders and Vaccination: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26160?fbclid=IwAR3C-QQc-ZDEDoCu0fWNQuVYzvbC3qYHGekCaicU5-l_bOUz4N52jl1wjJ0

Neurologic safety monitoring of COVID-19 vaccines, lessons learned from the past to inform the present: https://pubmed.ncbi.nlm.nih.gov/34475124/

Neurological side effects after first dose AstraZeneca and COVID-19 infection: https://pubmed.ncbi.nlm.nih.gov/34697502/

Covid Vaccines are not free of Neurologic side effects: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206845/

Combined central and peripheral demyelination with Anti-neurofascin155 IgG following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35107062/

Intracranial aneurysm rupture within 3 days of receiving mRNA vaccination: 3 case reports: https://pubmed.ncbi.nlm.nih.gov/35509565/

Cerebrovascular complications of COVID-19 and COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35420916/

**Neuropathy**

Small fiber neuropathy and POTS following Moderna and Pfizer vaccination (NIH publication): https://www.medrxiv.org/content/10.1101/2022.05.16.22274439v1?fbclid=IwAR3bhFglz5CRfS4zFd1QAP0bvIuk7XDXq7fDQxZwTYj0IzPE9C32lXDGqd4

Small fiber neuropathy: https://onlinelibrary.wiley.com/doi/10.1002/mus.27251…

COVID-19 vaccinations may not only be complicated by GBS but also by distal small fiber neuropathy: https://pubmed.ncbi.nlm.nih.gov/34525410/

Possible mechanisms of neuropathies associated with covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35119106/

Acute inflammatory neuropathies with COVID-19 vaccines: subgroup disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.gov/34579259/

Polyneuropathy in a 43yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35753790/

Recrudescence of severe polyneuropathy after receiving Pfizer vaccine in a patient with a history of eosinophilic granulomatosis with polyangiitis: https://pubmed.ncbi.nlm.nih.gov/35487626/

**POTS (Postural Orthostatic Tachycardia Syndrome):**

(See NIH Publication in neuropathy section above)

Postural orthostatic tachycardia syndrome after mRNA COVID-19 vaccine: https://link.springer.com/article/10.1007/s10286-022-00880-3 https://pubmed.ncbi.nlm.nih.gov/35870086/

POTS following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33968543/ https://www.cureus.com/articles/56242-a-case-of-postural-orthostatic-tachycardia-syndrome-secondary-to-the-messenger-rna-covid-19-vaccine

Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine https://academic.oup.com/ehjcr/article/5/12/ytab472/6444985

**Neuralgia:**

Neuralgia – Trigeminal, Amytrophy: Trigeminal neuritis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34870807/

Trigeminal Neuralgia and cervical radiculitis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34155020/

Neuralgic amyotrophy following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34347105/

Amyotrophic neuralgia secondary to AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34330677/

Neuralgic amyotrophy of the lumbosacral plexus following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34816739/

Parsonage-Turner syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34559695/

Parsonage-Turner syndrome in a 43yoM after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34936579/

2 cases of Parsonage Turner Syndrome following Moderna and Pfizer: https://pubmed.ncbi.nlm.nih.gov/34402669/

Parsonage—Turner syndrome following Astra Zeneca: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/34903275/

**Transverse Myelitis:**

36yoM with transverse myelitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/33787891/

Acute Myelitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34392078/

67yoF with transverse myelitis following Moderna 1st dose: https://pubmed.ncbi.nlm.nih.gov/34482455/

70yoM with acute autoimmune transverse myelitis following Moderna: https://pubmed.ncbi.nlm.nih.gov/34941191/

Longitudinal extensive transverse myelitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34507942/

Longitudinal extensive transverse myelitis in a 25yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34641797/

Longitudinal extensive transverse myelitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34182207/

Acute transverse myelitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34684047/

Transverse Myelitis and Bells Palsy after J&J vaccination: https://pubmed.ncbi.nlm.nih.gov/34458035/

Acute transverse myelitis in 43 patients post AstraZeneca Vaccination: https://pubmed.ncbi.nlm.nih.gov/33981305/

MOG-antibody associated longitudinal extensive myelitis after AstraZeneca in a 59yoM: https://pubmed.ncbi.nlm.nih.gov/34931927/

MOG antibody associated disease (38yoM) and transverse myelitis (39yoF) following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35755241/

**GBS (Guillain Barre Syndrome):**

12 cases of GBS and 4 cases of CIDP following COVID-19 vaccination in the UK: https://pubmed.ncbi.nlm.nih.gov/34786740/

24 cases of GBS following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34967005/

Sensory GBS in a 16yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35097156/

Sensory ataxic GBS with immunoglobulin G anti-GM1 antibodies following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34871447/

AstraZeneca and GBS: analysis using National Immunoglobulin Database: https://pubmed.ncbi.nlm.nih.gov/35180300/

GBS following Johnson and Johnson: https://www.onlinescientificresearch.com/articles/the-development-of-guillain-barre-syndrome-subsequent-to-administration-of-ad26cov2s-vaccine.pdf

GBS following 2nd dose of Pfizer:, electromyoneurography and laboratory findings: https://pubmed.ncbi.nlm.nih.gov/34347563/

3 cases of GBS in Alberta following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35747886/

GBS in a 23yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35528113/

Sensory ataxic GBS in a 80yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35342134/

GBS in a 58yoF with rapid onset and autonomic dysfunction following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35401916/

GBS in a 80yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/35441015/

GBS in a 25yoF following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34346014/

GBS following Pfizer in a 42yoM : https://pubmed.ncbi.nlm.nih.gov/34779385/

GBS in a 42yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34567447/

GBS in a 61yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34484780/

GBS in a 65yoM liver transplant patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34431208/

GBS in a 67yoM following 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34796417/

GBS in a 73yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34477091/

GBS in 73yoM following 2nd dose of Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253659/

GBS in 82yoF following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/33758714/

GBS 10 days after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34272622/

GBS 11 days after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34187803/

GBS following AstraZeneca with papilledema as atypical onset: https://pubmed.ncbi.nlm.nih.gov/34418708/

GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34330729/

GBS in a 63yo patient who had previous vaccine associated GBS syndrome following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34810163/

Recurrent GBS following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34468703/

3 cases of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34548920/

3 cases of GBS and 1 case of CIDP following AstraZeneca in Tasmania: https://pubmed.ncbi.nlm.nih.gov/34560365/

7 cases of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34114256/

19 cases of GBS following J&J, Pfizer, and Astra Zeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34644738/

GBS following vaccination, a review of 39 cases: https://pubmed.ncbi.nlm.nih.gov/34648420/

2 cases of Sensory GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416410/

Bilateral facial weakness with paresthesia variant of GBS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34261746/

Bifacial diplegia variant of GBS following J&J vaccination: https://pubmed.ncbi.nlm.nih.gov/34449715/

GBS presenting as bifacial diplegia in 2 patients following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34649856/

GBS following Johnson and Johnson: https://pubmed.ncbi.nlm.nih.gov/34550109/

GBS following Moderna: https://pubmed.ncbi.nlm.nih.gov/34767184/

GBS following 1st dose AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34217513/

GBS with Prominent Facial Diplegia after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34808658/

GBS in a 14yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34717201/

GBS in a 21yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34981285/

GBS in a 38yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34988954/

GBS in a 49yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34703690/

2 cases of GBS following Pfizer in patients in remission from b-cell lymphoma: https://pubmed.ncbi.nlm.nih.gov/34929194/

2 cases of GBS after Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34593364/

GBS following COVID-10 vaccination: a report of 2 cases: https://pubmed.ncbi.nlm.nih.gov/34599482/

Facial Diplegia variant of GBS in a 38yoM following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34538679/

Facial Diplegia variant of GBS in a 65yoF following J&J: https://pubmed.ncbi.nlm.nih.gov/34447646/

Axonal-variant GBS in 86yoF temporally associated with Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34722067/

**Miller Fisher Syndrome:**

Miller Fischer syndrome and GBS overlap syndrome after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34848426/

Miller Fisher syndrome in 24yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34817727/

Miller Fisher Syndrome in a 71yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34789193/

Miller Fisher syndrome after 2nd dose of Pfizer vaccination in a patient with resolved covid-19 https://pubmed.ncbi.nlm.nih.gov/34808657/

**Encephalopathy:**

75yoF with acute hemorrhagic necrotizing encephalopathy after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35098489/

32yoM with acute hyperactive encephalopathy after Moderna with dramatic response to methylprednisolone: https://pubmed.ncbi.nlm.nih.gov/34512961/

Facial Weakness, extremity weakness, encephalopathy, and severe refractory ITP following Moderna: https://pubmed.ncbi.nlm.nih.gov/33854395/

77yoM with acute encephalopathy and NSTEMI following Moderna: https://pubmed.ncbi.nlm.nih.gov/34703815/

**CIDP:**

Chronic inflammatory demyelinating polyneuropathy after following Moderna: https://pubmed.ncbi.nlm.nih.gov/35651399/

CIPD in a middle aged female following Moderna: https://pubmed.ncbi.nlm.nih.gov/35071987/

Acute onset chronic inflammatory demyelinating polyneuropathy (CIDP) after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34607818/

Chronic inflammatory demyelinating polyneuropathy after AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34960248/

**Akathisia:**

Transient akathisia after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34113842/

**Phantosmia:**

Phantosmia: https://pubmed.ncbi.nlm.nih.gov/34096896/

**Bells Palsy / Nerve Palsy:**

Multiple cranial nerve palsies following COVID-19 vaccination (Pfizer): https://pubmed.ncbi.nlm.nih.gov/34725821/

Acute abducens nerve palsy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34044114/

Acute aducens nerve palsy following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34851785/

Acute Abducens nerve palsy following vaccination: https://pubmed.ncbi.nlm.nih.gov/34827043/

21yoF nurse with Bells Palsy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34322761/

34yoF with Bells Palsy 2 days after Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143982/

36yo with Bells Palsy, left arm tingling/numbness/weakness following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34336436/

32yoF with Bells Palsy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35759681/

37yoM with Bells Palsy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/33611630/

50yoM with Bells Palsy after Pfizer, ongoing symptoms after 21 days: https://pubmed.ncbi.nlm.nih.gov/34330676/

57yoF with Bells Palsy <36 hours after 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/33594349/

61yoM with Bells Palsy after each dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34281950/

Bells Palsy following mRNA and inactivated (CoronaVac) vaccines: a case series and nested case-control study: https://pubmed.ncbi.nlm.nih.gov/34411532/

Rate of Bells Palsy following mRNA vaccination is 2-3x higher then expected: https://pubmed.ncbi.nlm.nih.gov/34111409/

**Neuromyelitis Optica:**

New onset neuromyelitis optica spectrum disorder following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35184119/

Neuromyelitis optic in a healthy female following Moderna: https://pubmed.ncbi.nlm.nih.gov/34660149/

Neuromyelitis optica spectrum disorder (NMOSD): https://link.springer.com/article/10.1007/s10072-021-05427-4?fbclid=IwAR2DGcW8Y5UxvdzcOQaBUPn6_RTZGQRSsNo6bzanyAm9yN6387E3Z6WrKII

Antibody positive neuromyelitis optica spectrum disorder after 2nd dose Pfizer in a 80yoM: https://pubmed.ncbi.nlm.nih.gov/35761845/

Optic neuropathy after Pfizer and Astrazeneca: a report of 2 cases: https://pubmed.ncbi.nlm.nih.gov/34906029/

Bilateral optic neuritis after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35098359/

Optic neuritis and transverse myelitis in MS patient after Astrazeneca vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205198/

**Multiple Sclerosis:**

Patient's first MS Flare following Pfizer https://link.springer.com/article/10.1007/s00415-021-10648-w

New onset MS in a 32yoF patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34804388/

New onset of MS in a 40yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34700047/

3 new cases of MS, 13 flares of MS after Pfizer, Moderna, and Astra Zeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34744992/

4 cases of activation of stable MS, 2 cases of new MS, 1 case of new onset neuromyelitis optica after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34480607/

COVID infection and vaccination outcomes in multiple sclerosis: https://pubmed.ncbi.nlm.nih.gov/35747550/

Severe Multiple Sclerosis relapse after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34447349/

5 cases of new diagnosis of multiple sclerosis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34922126/

Optic neuritis and transverse myelitis in MS patient after Astrazeneca vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8205198/

**Myasthenia Gravis:**

Vaccination associated Ocular Myasthenia Gravis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35077038/

Myasthenia Gravis Flare Following Moderna: https://www.cureus.com/articles/60348-a-case-of-covid-19-vaccine-causing-a-myasthenia-gravis-crisis

Fatal Myasthenic Crisis in a 55yoM following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35449619/

New onset Myasthenia Gravis in 82yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34709075/

**Cerebral Venous Thrombosis:**

Thromboembolic events following mRNA COVID vaccination, a case series: https://pubmed.ncbi.nlm.nih.gov/35118582/

CVA and Thrombocytopenia following Astrazeneca: https://pubmed.ncbi.nlm.nih.gov/34175640/

Cerebral venous sinus thrombosis after Moderna in a 56yoF: https://pubmed.ncbi.nlm.nih.gov/35181646/

Extensive cerebral venous sinus thrombosis after 1st dose Pfizer without TTS in a 28yoF: https://pubmed.ncbi.nlm.nih.gov/35136010/

Cerebral venous thrombosis due to VITT after 2nd dose of AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35263427/

Age-stratified risk of cerebral venous sinus thrombosis after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34921101/

Characteristic of outcomes in patients with cerebral venous sinus thrombosis in COVID vaccine induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34581763/

Cerebral venous sinus thrombosis in setting of COVID-19 vaccination: a systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/35394172/

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after J&J: https://pubmed.ncbi.nlm.nih.gov/33929487/

Cerebral venous thrombosis in a 61yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34796065/

Cerebral venous sinus thrombosis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34783932/

Central venous sinus thrombosis with subarachnoid hemorrhage in a 45yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34478433/

Cerebral venous sinus thrombosis after AstraZeneca, neurologic and radiological management: https://pubmed.ncbi.nlm.nih.gov/34327553/

Cerebral venous sinus thrombosis, subarachnoid hemorrhage, and thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34485807/

Cerebral Venous sinus thrombosis, review of European cases: https://pubmed.ncbi.nlm.nih.gov/34293217/

Review of European data of Cerebral venous thrombosis with cytopenia, observed in Pfizer, Moderna, and AstraZeneca https://pubmed.ncbi.nlm.nih.gov/34375510/

A multicenter cohort study of cerebral venous thrombosis after AstraZeneca Vaccination: https://pubmed.ncbi.nlm.nih.gov/34370972/

Endovascular treatment for AstraZeneca induced cerebral venous sinus thrombosis and thrombocytopenia, a report of 3 cases: https://pubmed.ncbi.nlm.nih.gov/34782400/

45 cases of Cerebral Venous thrombosis: https://pubmed.ncbi.nlm.nih.gov/34288044/

International Cerebral Venous Thrombosis consortium report on cerebral venous thrombosis following vaccination against SARS-COV-2: https://pubmed.ncbi.nlm.nih.gov/34462996/

Spontaneous rare visceral pseudoaneurysm presenting with rupture after Moderna: https://pubmed.ncbi.nlm.nih.gov/34480824/

**Intracerebral Hemorage / Strokes / etc:**

Fatal ICH following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34477089/

ICH due to vasculitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34783899/

Treatment of AstraZeneca induced immume thrombotic thrombocytopenia related acute ischemic stroke: https://pubmed.ncbi.nlm.nih.gov/34461442/

Symptomatic penducular, cavernous bleeding following Pfizer vaccination induced ITP: https://pubmed.ncbi.nlm.nih.gov/34549178/

Lobar bleeding with ventricular rupture shortly following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34729467/

Bilateral thalamic stroke following Pfizer: a case of VITT? https://pubmed.ncbi.nlm.nih.gov/34820232/

**Aphasia:**

Aphasia 7 days after 2nd dose of mRNA based vaccine due to intracerebral bleeding in left temporal lobe: https://pubmed.ncbi.nlm.nih.gov/34192245/

**Neuro-Oncologic:**

Worsening Neuro-Oncologic Disease Symptoms following mRNA vaccination: https://www.cureus.com/articles/61880-new-onset-neurologic-symptoms-and-related-neuro-oncologic-lesions-discovered-after-covid-19-vaccination-two-neurosurgical-cases-and-review-of-post-vaccine-inflammatory-responses

**Headache / Aseptic Meningitis:**

18yoM with aseptic meningitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34711784/

Aseptic meningitis, mucocutaneous lesions, and arthritis after Pfizer in a 15yoM: https://pubmed.ncbi.nlm.nih.gov/35214783/

Aseptic meningitis in a 34yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34882515/

Headache after AstraZeneca: a MultiCenter observational cohort center: https://pubmed.ncbi.nlm.nih.gov/34313952/

Status migrainosus following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34807361/

Characteristics of COVID vaccine induced Headache: https://pubmed.ncbi.nlm.nih.gov/34510919/

Clinical characteristics of Headache following Pfizer, a multicenter observational cohort study: https://pubmed.ncbi.nlm.nih.gov/34405142/

Aseptic Meningitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34378098/

Aseptic meningitis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34777795/

Steroid responsive aseptic meningitis after Pfizer in a 62yoF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566612/

**Encephalitis / Delirium:**

Delirium in an elderly patient following vaccination: https://pubmed.ncbi.nlm.nih.gov/33829614/

Two cases of encephalopathy and seizures following Moderna: https://pubmed.ncbi.nlm.nih.gov/34367780/

Acute meningoencephalitis in a 72yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35283382/

Acute encephalitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35748025/

Anti-LGI1 encephalitis following COVID-19 vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/35751687/

69yoF with acute transient encephalopathy following Moderna: https://pubmed.ncbi.nlm.nih.gov/35702446/

Acute disseminated encephalitis following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294707/

Acute disseminated encephalomyelitis (ADEM) following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34735684/

ADEM with bilateral optic neuritis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35151258/

Acute disseminated encephalomyelitis (ADEM) in a 88yoF following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34841097/

COVID-19 Moderna booster induced autoimmune encephalitis in a 48yoM: https://pubmed.ncbi.nlm.nih.gov/35182374/

Anti-LGI1 encephalitis in a 48yoM following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35751687/

Autoimmune encephalitis in a 35yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35021289/

Case report of AstraZeneca associated encephalitis in a 22yoF: https://pubmed.ncbi.nlm.nih.gov/34903200/

Acute Disseminated Encephalitis in a young female following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34480527/

Postvaccinal encephalitis followingAstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34324214/

Acute encephalitis, myoclonus, and sweet syndrome after mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34312136/

Acute psychosis due to anti-NMDA encephalitis in a young female in her 20s following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34803896/

First episode of psychosis in 18yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35091388/

New onset psychosis in 31yoM after mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34388513/

**Other:**

COVID-19 vaccine associated parkinson's disease, a prion disease signal in UK yellow card adverse event database: https://www.semanticscholar.org/paper/COVID-19-Vaccine-Associated-Parkinson%27s-Disease%2C-A-Classen/0fe033bb1e274f27bc7c1703f09206e2965c75ca

COVID-19 RNA based vaccines and the risk of prion disease: https://www.semanticscholar.org/paper/COVID-19-RNA-Based-Vaccines-and-the-Risk-of-Prion-Classen/68580738ad152158a095c2f90a2a28a4c8b5d7d2

Clinical and radiological follow-up of Pfizer induced hemichorea hemiballismus in a 90yoM: https://pubmed.ncbi.nlm.nih.gov/35646423/

Polyneuritis cranialis, a rare GBS variant, associated with Pfizer in a 16yoF: https://pubmed.ncbi.nlm.nih.gov/35062795/

Reversible radiculomyelitis after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35110289/

Severe dyskinesia in Parkinson Patient following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34368991/

Hemichorea following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34811599/

3 cases of worsening complex regional pain syndrome following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34809486/

Cytotoxic lesion of the Corpus Callousum following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34402238/

Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34432055/

Two patients with schizophrenia treated with clozapine develop neutropenia after COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/35115846/

Three cases: CVA, left facial nerve palsy, and myelitis all following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34507266/

## Pulmonar:

Vaccine induced interstitial lung disease in 86yoM after mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34362838/

Vaccine induced interstitial lung disease: https://pubmed.ncbi.nlm.nih.gov/34510014/

Delayed hypersensitivity to Pfizer presenting with pneumonitis and rash: https://pubmed.ncbi.nlm.nih.gov/34813953/

Pfizer vaccine induced Pneumonitis in a 65yoM: https://pubmed.ncbi.nlm.nih.gov/34707048/

Interstitial lung disease in a 71yoF after receiving mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/35223425/

2 cases (67yoM and 70yoM) of Pfizer related interstitial lung disease: https://pubmed.ncbi.nlm.nih.gov/35355663/

Pulmonary embolus and DVT in a 14yoM after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35173114/

2 cases of eosinophilic pneumonia following vaccination: https://pubmed.ncbi.nlm.nih.gov/34803208/

Interstitial lung disease after COVID-19 vaccination may be more common in Asians: https://pubmed.ncbi.nlm.nih.gov/34850213/

Acute eosinophilic pneumonia in a 37yo M following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34803207/

Acute eosinophilic pneumonia following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34812326/

Pulmonary Embolus following Moderna: https://pubmed.ncbi.nlm.nih.gov/34452028/

2 cases of Pulmonary embolus following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34804412/

## Cardiovascular:

**General:**

Rationale for the Treatment of Long-Covid and Post Vax Symptoms – A cardiologists View: https://www.frontiersin.org/articles/10.3389/fcvm.2022.992686/abstract

Cardiovascular and hematological events post COVID-19 vaccination: a systemic review: https://pubmed.ncbi.nlm.nih.gov/34967105/

American Heart Association: Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056583

American Heart Association: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines https://www.ahajournals.org/doi/abs/10.1161/circ.144.suppl_1.10712

Note the distinction between myocarditis, novel coronavirus myocarditis, and covid-19 vaccine associated myocarditis: https://pubmed.ncbi.nlm.nih.gov/34791441/

JAMA article, concerns for perimyocarditis underreporting, review of 40 hospitals: https://jamanetwork.com/journals/jama/fullarticle/2782900

Intravenous injection of mRNA vaccine can induce acute myopericarditis in mouse model: https://pubmed.ncbi.nlm.nih.gov/34406358/

The Novel platform of mRNA vaccines and myocarditis: clues into the potential underlying mechanism: https://pubmed.ncbi.nlm.nih.gov/34312010/

Proposed pathogenesis, characteristics, and management of mRNA related myopericarditis: https://pubmed.ncbi.nlm.nih.gov/34817850/

mRNA and Pericarditis/myocarditis risk compared to other vaccine types: https://pubmed.ncbi.nlm.nih.gov/34834458/

ACS risk factor biomarkers increase after mRNA vaccination: https://www.thecardiologyadvisor.com/home/topics/acs/acute-coronary-syndrome-acs-biomarkers-mrna-covid19-vaccine/?s=09&fbclid=IwAR2SRmzW0Aj1dESMuJlTTcZHAHbRIIdl6C2Hpztm8Co_46AV5qss_4-3NV8

A review of cardiac side effects from Pfizer and Moderna in Singapore: https://pubmed.ncbi.nlm.nih.gov/34808708/

Fatal fulminant necrotizing eosinophilicy myocarditis following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/34978002/

Immune mediated necrotizing myopathy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34970746/

Severe necrotizing myopathy after Pfizer and regimen of ipulimumab plus nivolumab in a patient with advanced melanoma: https://pubmed.ncbi.nlm.nih.gov/34661938/

**Myocarditis – Pericarditis – Reports:**

1077 cases of myocarditis and 1149 pericarditis following vaccination in Nordic residents, a cohort study: https://pubmed.ncbi.nlm.nih.gov/35442390/

1626 cases of myocarditis in VAERS from Dec 2020-augut 2021, a review (JAMA): https://pubmed.ncbi.nlm.nih.gov/35076665/

Myocarditis/myopericarditis in 269 individuals, a population based Danish cohort study: https://pubmed.ncbi.nlm.nih.gov/34916207/

Myocarditis in adolescents and adults following vaccination in 2021, review of 238 cases: https://pubmed.ncbi.nlm.nih.gov/35449353/

Review of 40 published case reports of myocarditis following covid vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887934/

Myopericarditis recurrence in a 27yoM after 3rd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35602257/

Biopsy proven fulminant myocarditis in a 48yoF following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35187464/

Fulminant myocarditis in a 80yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35088026/

8 cases of myocarditis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34133884/

COVID-19 vaccine, myocardial infarction, and Kounis syndrome: https://pubmed.ncbi.nlm.nih.gov/35104343/

Myocarditis in a 17yoM following vaccination: https://pubmed.ncbi.nlm.nih.gov/35105392/

4 cases of myocarditis following Pfizer booster in Israel: https://pubmed.ncbi.nlm.nih.gov/35100809/

Moderna associated myopericarditis in a patient with a subclinical autoimmune predisposition: https://pubmed.ncbi.nlm.nih.gov/34868402/

Perimyocarditis in teens: https://pubmed.ncbi.nlm.nih.gov/34077949/

Vaccination associated myocarditis in Adolescents: https://pubmed.ncbi.nlm.nih.gov/34389692/

mRNA vaccination and myocarditis in adolescents: https://pubmed.ncbi.nlm.nih.gov/34393110/

Association of myocarditis with mRNA vaccination, a case review in children: https://pubmed.ncbi.nlm.nih.gov/34374740/

STEMI mimic: focal myocarditis in an adolescent patient after mRNA COVID-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/34756746/

Recurrence of myocarditis after vaccination https://pubmed.ncbi.nlm.nih.gov/34166671/

Acute Myocardial Injury following COVID-19 vaccination: a case report and review of current evidence from VAERS: https://pubmed.ncbi.nlm.nih.gov/34219532/

Myocarditis in a 27yoM following Pfizer: CMR features: https://pubmed.ncbi.nlm.nih.gov/35626190/

Myocarditis in a 17yo Japanese male following Moderna: https://pubmed.ncbi.nlm.nih.gov/35495897/

Myocarditis and/or pericarditis after mRNA vaccination: head to head comparison of Moderna versus Pfizer: https://pubmed.ncbi.nlm.nih.gov/35750537/

Fulminant myocarditis requiring ECMO in a 60yoF following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35650138/

Acute pericarditis following mRNA booster: https://pubmed.ncbi.nlm.nih.gov/35308666/

Myocarditis or pericarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35749119/

Myocarditis with hemorrhagic pericardial effusion following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35646594/

Myopericarditis in young adults presenting to the ED: https://pubmed.ncbi.nlm.nih.gov/34310793/

Pericarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34364831/

Symptomatic pericarditis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34693198/

Myocarditis following J&J in a healthy, young male: https://pubmed.ncbi.nlm.nih.gov/34420869/

Acute myocarditis after Moderna in young male: https://pubmed.ncbi.nlm.nih.gov/34308326/

Myocarditis in a healthy male: https://pubmed.ncbi.nlm.nih.gov/34229940/

Acute myocarditis following vaccination: https://pubmed.ncbi.nlm.nih.gov/34331307/

Acute myocarditis following Pfizer in a healthy man with previous COVID infection: https://pubmed.ncbi.nlm.nih.gov/34367386/

Acute fulminant myocarditis following mRNA vaccination requiring ECMO: https://pubmed.ncbi.nlm.nih.gov/34778411/

Myocarditis case report: https://pubmed.ncbi.nlm.nih.gov/34118375/

Case report: probable myocarditis after mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/

Myocarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34393273/

A late presentation of vaccine induced myocarditis: https://pubmed.ncbi.nlm.nih.gov/34660088/

Myocarditis in 24yoM: https://pubmed.ncbi.nlm.nih.gov/34268277/

Myocarditis in a 24yoM nurse after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34400043/

Myocarditis in a 15yo following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369878/

Myopericarditis in a 16yo following vaccination https://pubmed.ncbi.nlm.nih.gov/34133825/

Myocarditis in a 16yo, late gadolinium enhancement: https://pubmed.ncbi.nlm.nih.gov/34778788/

Myocarditis in a 22yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34348657/

4 cases of myocarditis after 3rd dose of Pfizer: magnetic resonance imaging study (18-44yo): https://pubmed.ncbi.nlm.nih.gov/35310989/

5 cases of myocarditis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34092429/

7 cases of myocarditis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35479661/

Myocarditis presenting with hyperechoic nodule in a 17yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35470603/

Myocarditis in a 18yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34804729/

Myocarditis in a middle aged male with significant left ventricular dysfunction following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34795198/

70yoF with myocarditis following J&J Vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270733/

Biopsy proven lymphocytic myocarditis following 1st mRNA vaccination in a 40yo: https://pubmed.ncbi.nlm.nih.gov/34487236/

Cardiac imaging of acute myocarditis following mRNA in a 24yoM: https://pubmed.ncbi.nlm.nih.gov/34402228/

Cardiac MRI findings in young adults following mRNA vaccination: a case series: https://pubmed.ncbi.nlm.nih.gov/34496880/

Case report: probable myocarditis after mRNA vaccine in a patient with arrhythmogenic left ventricular cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34712717/

Myocarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34393273/

A rare case of myocarditis and pulmonary embolism after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35343473/

A late presentation of vaccine induced myocarditis: https://pubmed.ncbi.nlm.nih.gov/34660088/

5 cases of myocarditis after Pfizer (age 16 and up): https://pubmed.ncbi.nlm.nih.gov/34092429/

Myocarditis in a 13yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35475062/

Follow-up cardiac magnetic resonance in 7 children with Pfizer vaccine associated myocarditis (80% with persistent abnormalities at 90 days): https://pubmed.ncbi.nlm.nih.gov/35482094/

7 cases of myocarditis after mRNA vaccination (age 16 and up): https://pubmed.ncbi.nlm.nih.gov/35479661/

Followup CMR imaging in 15 patients 6 months after Pfizer associated myocarditis (age 14-19): https://pubmed.ncbi.nlm.nih.gov/35320390/

Follow-up cardiac magnetic resonance (CMR) in 7 children with Pfizer vaccine associated myocarditis: https://pubmed.ncbi.nlm.nih.gov/35482094/

Followup CMR imaging in 15 patients 6 months after Pfizer associated myocarditis: https://pubmed.ncbi.nlm.nih.gov/35320390/

2 cases of myocarditis presenting with ST segment elevation in adolescent males after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34180390/

Cardiac complications following mRNA vaccination: a systematic review of case reports and case series: https://pubmed.ncbi.nlm.nih.gov/34921468/

Myopericarditis following mRNA vaccination: the role of cardiac biomarkers and multimodality imaging: https://pubmed.ncbi.nlm.nih.gov/34487161/

Myocarditis should be consider in those with a troponin rise and unobstructed arteries following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34463755/

Myocarditis Associated with COVID-19 vaccination: echocardiography, cardiac tomography, and magnetic resonance imaging findings: https://pubmed.ncbi.nlm.nih.gov/34428917/

Cardiac magnetic resonance characteristics of acute myocarditis occuring after mRNA vaccine immunization: https://pubmed.ncbi.nlm.nih.gov/34787887/

Fulminant myocarditis and systemic hyperinflammation in 2 patients following mRNA: https://pubmed.ncbi.nlm.nih.gov/34416319/

2 cases of histological confirmed myocarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34407340/

Myocarditis and Pericarditis: 2 case reports: https://pubmed.ncbi.nlm.nih.gov/34277198/

Two cases of myocarditis https://pubmed.ncbi.nlm.nih.gov/34166884/

3 cases of cardiac manifestation following Pfizer: https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab177/6311674

4 cases of Myocarditis and their Cardiac MRI findings: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245050/

4 cases of myocarditis: https://pubmed.ncbi.nlm.nih.gov/34396358/

6 cases of men age 17-37 with myocarditis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8219373/

8 cases of myocarditis in adolescents following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34319393/

13 cases of Myocarditis in adolescents following Pfizer: https://www.jpeds.com/article/S0022-3476(21)00665-X/fulltext

Review of 15 published cases of myocarditis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272967/

Myocarditis and pericarditis due to mRNA vaccines in 19 cases: https://pubmed.ncbi.nlm.nih.gov/34805376/

Myocarditis in 23 military members: https://jamanetwork.com/journals/jamacardiology/fullarticle/2781601

Review of 29 published cases of acute myopericarditis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34356586/

Review of 214 myocarditis cases:: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233865/

**Cardiomyopathy:**

Covid-19 vaccine associated Takotsubo cardiomyopathy: https://pubmed.ncbi.nlm.nih.gov/34375049/

63yoF with Takotsubo cardiomyopathy following Moderna: https://pubmed.ncbi.nlm.nih.gov/34330629/

Reverse takotsubo cardiomyopathy as a cause of acute chest pain in a young woman following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34961327/

**Acute MI (Myocardial Infarction):**

3 cases of acute infarct-like myocarditis (2 Pfizer, 1 AstraZeneca): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325525/

2 cases of acute MI <24 hours after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34364657/

Acute STEMI MI following AstraZeneca vaccination,?Kounis syndrome?: https://pubmed.ncbi.nlm.nih.gov/34394944/

Vaccine induced immune thrombocytopenia and thrombosis associated anterior ST-elevation myocardial infarction following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34486030/

**Hypertension:**

Hypertension following mRNA vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8206586/

**POTS (Postural Orthostatic Tachycardia Syndrome):**

Postural orthostatic tachycardia syndrome after mRNA COVID-19 vaccine: https://link.springer.com/article/10.1007/s10286-022-00880-3 https://pubmed.ncbi.nlm.nih.gov/35870086/

POTS following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33968543/ https://www.cureus.com/articles/56242-a-case-of-postural-orthostatic-tachycardia-syndrome-secondary-to-the-messenger-rna-covid-19-vaccine

Autonomic dysfunction post-inoculation with ChAdOx1 nCoV-19 vaccine https://academic.oup.com/ehjcr/article/5/12/ytab472/6444985

**Tachycardia:**

Isolated tachycardia in a 29yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34466331/

Tachycardia following Pfizer: 3 cases in those previously infected with COVID-19: https://pubmed.ncbi.nlm.nih.gov/33858709/

**Long QT / Conduction Disturbance:**

VT storm in long QT resulting from COVID-19 vaccine allergy treated with epinephrine: https://pubmed.ncbi.nlm.nih.gov/34791122/

Long QT syndrome following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34804335/

Two cases of vaccine induced cardiac conduction disturbance following Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34796078/

Dizziness, HTN and new LBBB following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34508485/

Frequent PVS and NSVT following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34275963/

Unmasked type 1 Brugada pattern without fever in a 32yoM following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776624/

**Other:**

Posttransplant lymphoproliferative disorder after AstraZeneca in a heart transplant recipient: https://pubmed.ncbi.nlm.nih.gov/34702598/

## Gastrointestinal:

Risk of adverse events and reported relapse after COVID-19 vaccination in patients with IBD: https://pubmed.ncbi.nlm.nih.gov/34819330/

**Gastroparesis:**

Gastroparesis following Pfizer: https://journals.lww.com/ajg/Citation/9900/Gastroparesis_After_Pfizer_BioNTech_COVID_19.28.aspx

**Pancreas:**

14yoF with acute pancreatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35081801/

17yoM with acute pancreatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35053654/

71yoF with acute pancreatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35029194/

Pancreatitis injury after Pfizer, a case report: https://pubmed.ncbi.nlm.nih.gov/34205898/

Acute Necrotizing Pancreatitis following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34423463/

Acute Pancreatitis in a 96yoF following 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34084669/

Pancreas allograft rejection following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34781027/

**Hepatitis:**

Cutaneous hypersensitivity reaction with acute hepatitis following Pfizer 2nd dose: https://pubmed.ncbi.nlm.nih.gov/34485657/

35yoF third month post partum with autoimmune hepatitis following vaccination: https://pubmed.ncbi.nlm.nih.gov/33862041/

Liver transplant in a 53yo healthy man due to vaccine induced autoimmune hepatitis and subsequent liver failure following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/35175635/

65yoM with autoimmune hepatitis following Moderna: https://pubmed.ncbi.nlm.nih.gov/34717185/

79yoM with AstraZeneca induced autoimmune hepatitis: https://pubmed.ncbi.nlm.nih.gov/35013724/

Three cases of autoimmune hepatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34904265/

A case of hepatotoxicity in 14yoF after receiving Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35070524/

Post-transplant autoimmune recurrence following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/35390478/

27yoF with autoimmune hepatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35437965/

82yoF with history of HCV treatment with autoimmune hepatitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35716255/

Development of hepatitis and colitis in a 52yoF with cancer during immunotherapy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35694999/

Severe de novo liver injury after Moderna vaccination-not always autoimmune hepatitis: https://pubmed.ncbi.nlm.nih.gov/35439566/

Liver injury and cytopenia in an adolescent following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35510521/

Clinical significance of hepatosplenic thrombosis in VITT after AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34958931/

AMA-positive hepatitis in a 56yoF induced by Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35040333/

Hepatic artery occlusion following Astrazeneca: https://pubmed.ncbi.nlm.nih.gov/34926142/

Acute cholestatic hepatitis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34256064/

52yoF with autoimmune hepatitis following Moderna: https://onlinelibrary.wiley.com/doi/10.1111/liv.15092

41yo F with Autoimmune hepatitis following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197609/

76yoF with autoimmune hepatitis following Moderna Vaccination: https://pubmed.ncbi.nlm.nih.gov/34332438/

71yoF with Autoimmune hepatitis after mRNA vaccine (Moderna): https://www.sciencedirect.com/science/article/pii/S0168827821018961?via%3Dihub

80yoF with autoimmune hepatitis following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8186938/

63yoM with autoimmune hepatitis following Moderna: https://pubmed.ncbi.nlm.nih.gov/34293683/

61yoF with liver injury following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34430106/

61yoF with autoimmune hepatitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34781161/

35yoF with autoimmune hepatitis following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/

New Onset autoimmune hepatitis following mRNA vaccination in a 36yoF with Primary sclerosing cholangitis: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384483/

56yoF with autoimmune hepatitis following Moderna: https://www.journal-of-hepatology.eu/article/S0168-8278(21)00424-4/fulltext

Two cases of autoimmune hepatitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34225251/

Liver injury in a liver transplant patient following mRNA vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214934/

16 cases of liver injury following Pfizer and Moderna: a multicenter case series: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324396/

Reactivation of Hepatitis C infection following Pfizer in a 82yoF: https://www.dovepress.com/hepatitis-c-virus-reactivation-following-covid-19-vaccination–a-case–peer-reviewed-fulltext-article-IMCRJ?fbclid=IwAR3u0x1baFcAZz1eOrNsXsgmrlUYt0EJV2SmoXA75RiplFQbPrtSAIo2GAs

**Other:**

Inflammatory Bowel Disease triggered by Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34922342/

De Novo Pediatric Ulcerative Colitis trigger by Pfizer: a tale of 2 sisters: https://pubmed.ncbi.nlm.nih.gov/35762665/

Ischemic colitis in a 48yoF after 2nd dose of covid019 inactivated vaccine: https://pubmed.ncbi.nlm.nih.gov/35647139/

Sclerosing Cholangitis: https://pubmed.ncbi.nlm.nih.gov/34450237/

Unusual fever, HA, and abdominal pain in a healthy woman following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34339677/

Hepatic vein thrombosis due to TTS following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34432063/

3 cases of portal vein thrombosis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34776709/

## Renal:

**ANCA:**

ANCA glomerulonephritis after Moderna: https://www.kidney-international.org/article/S0085-2538(21)00555-X/fulltext

Case report: ANCA vasculitis with acute renal failure and pulmonary hemorrhage after Moderna: https://pubmed.ncbi.nlm.nih.gov/34859017/

New onset ANCA vasculitis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34280507/

ANCA associated Glomerulonephritis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34423176/

ANCA associated vasculitis presenting with Rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34659268/

Anti-GBM nephritis with mesangial IgA deposits following Moderna: https://pubmed.ncbi.nlm.nih.gov/34119511/

Concurrent antiglomerular basement membrane (Anti-GBM) nephritis and ANCA glomerulonephritis in a 23yoM following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/34746518/

Two adolescent cases of acute tubulointerstitial nephritis after 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35385678/

58yoF with Pfizer induced severe rhabdomyolysis with acute AKI requiring renal replacement therapy: https://pubmed.ncbi.nlm.nih.gov/35747054/

De novo and relapsing necrotizing vasculitis after mRNA vaccination, 5 cases: 4 cases of relapsing ANCA vasculitis and 1 de novo polyarteritis nodosa: https://pubmed.ncbi.nlm.nih.gov/35211310/

COVID-19 vaccination precipitating de novo ANCA associated vasculitis: clinical implications: https://pubmed.ncbi.nlm.nih.gov/35498903/

PTU-induced ANCA-associated vasculitis after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34451967/

Relapsed ANCA associated vasculitis following AstraZeneca: A case series of two patients: https://pubmed.ncbi.nlm.nih.gov/34755433/

ANCA associated vasculitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416184/

**Nephrotic Syndrome:**

Nephrotic Syndrome following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257404/

New onset pediatric nephrotic syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34782983/

Nephrotic syndrome and vasculitis following Pfizer, Moderna, and AstraZeneca: https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfab215/6318785

**Minimal Change Disease:**

MCD relapse following Pfizer in a man in his mid-60s: https://pubmed.ncbi.nlm.nih.gov/34023417/

MCD relapse following Pfizer in a 34yoF: https://pubmed.ncbi.nlm.nih.gov/33964312/

Severe Minimal change disease relapse 3 days following Pfizer: https://europepmc.org/article/pmc/pmc8156905

Minimal Change Disease with nephrotic syndrome and AKI following Pfizer in a 50yoM: https://pubmed.ncbi.nlm.nih.gov/33839200

Minimal change disease in a 18yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35611026/

Minimal change disease in a 25yoF following 1st dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35435622/

Minimal change disease following Pfizer in a living kidney donor: https://pubmed.ncbi.nlm.nih.gov/35056345/

2 cases of nephrotic syndrome with minimal change disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35246429/

Minimal change disease in 80's yoM following first dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/33992727/

Minimal change disease after 1st dose Pfizer 60yoM: https://pubmed.ncbi.nlm.nih.gov/34804557/

Minimal change disease and AKI in a 77yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34000278/

Minimal change disease 4 days after Pfizer in a 45yoF: https://pubmed.ncbi.nlm.nih.gov/34721864/

Minimal change disease in a 39yo after 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34143368/

Minimal Change disease in a 63yoF following Moderna: https://pubmed.ncbi.nlm.nih.gov/34048824/

Minimal change disease in a 43yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34052236/

Relapse of minimal change disease with severe nephrotic syndrome in a 22yoM following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156905/

Minimal Change disease and Severe AKI following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34242687/

Relapse of Minimal Change disease in a 30yoM following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34119512/

New onset Nephrotic syndrome due to Minimal Change disease following J&J: https://pubmed.ncbi.nlm.nih.gov/34342187/

2 cases of minimal change disease following vaccination: https://pubmed.ncbi.nlm.nih.gov/34779088/

3 cases of minimal change disease following 2nd dose of mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34337193/

13 cases of new or relapsing minima change disease following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34632166/

**Nephropathy / IGA Vasculitis:**

Acute interstitial nephritis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35113012/

Sibling cases of IgA nephropathy (15yoM and 18yoM) following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35729514/

IgA nephropathy in a 12yoM after 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35339305/

IgA nephropathy relapse in a 54yoF following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35392838/

2 cases of macroscopic hematuria in children with IgA nephropathy remission following Pfizer (15yoF, 16yoF): https://pubmed.ncbi.nlm.nih.gov/35301586/

2 cases (19yoM, 50yoF), histologic correlates of gross hematuria following Moderna in patients with IgA nephropathy (recurrence of disease following vaccination): https://pubmed.ncbi.nlm.nih.gov/34146600/

Acute T-cell mediated rejection after Pfizer in a kidney transplant recipient: https://pubmed.ncbi.nlm.nih.gov/35769849/

Abrupt worsening of occult IgA nephropathy after first dose Pfizer in a Japanese woman in her 40s: https://pubmed.ncbi.nlm.nih.gov/34988883/

Development of IgA vasculitis with severe glomerulonephritis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35275366/

New onset kidney biopsy proven IgA vasculitis in a 47yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/35075622/

2 cases of IgA vasculitis following Pfizer (22yoM and 30yoM): https://pubmed.ncbi.nlm.nih.gov/35253880/

19 cases of IgA vasculitis post COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35229346/

Acute interstitial nephritis in a 63yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35254639/

2 cases of acute interstitial nephritis with concurrent nephrotic syndrome (69yoF and 60yoF) following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35211313/

New-onset kidney diseases after COVID-19 vaccination: a case series (5 patients): https://pubmed.ncbi.nlm.nih.gov/35214760/

Glomerular disease in temporal association with COVID-19 vaccination: a series of 29 cases: https://pubmed.ncbi.nlm.nih.gov/35372991/

New onset biopsy proven nephropathies after COVID vaccination, 17 patients: https://pubmed.ncbi.nlm.nih.gov/35354140/

New-onset and relapse of nephrotic syndrome following COVID-19 vaccination, 27 patients in Japan, a questionnaire survey: https://pubmed.ncbi.nlm.nih.gov/35569069/

Clinical spectrum of gross haematuria following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35498904/

Atypical haemolytic uraemic syndrome following Pfizer in a 60yoF: https://pubmed.ncbi.nlm.nih.gov/35756730/

A case of acute interstitial nephritis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34219853/

Acute interstitial nephritis in a 45yoF following 2 doses of Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650829/

Isolated renal arteritis with infarction after Pfizer COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35095058/

13 cases of new or relapsed glomerulonephritis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34632166/

48 cases of new onset and relapsed kidney histopathology following COVID-19 vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622870/

New onset lupus in a 68yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35294664/

New onset of Class III lupus nephritis with multi-organ involvement after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35108572/

IgA nephropathy presenting as rapidly progressive glomerulonephritis in a 13yo following 1st dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34786589/

IgA and crescentic glomerulonephritis following Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141343/

17yoM with newly diagnosed IgA nephropathy with gross hematuria following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34865167/

17yoF with IgA nephropathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35118635/

IgA nephropathy in a 28yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35110484/

28yoF with flare up of IgA nephropathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35108771/

29yoF with hematuria and likely IgA nephritis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35102819/

IgA nephropathy flare up following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079938/

IgA Nephropathy after mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34278290/

IgA nephropathy flare-up following vaccination: https://pubmed.ncbi.nlm.nih.gov/34415336/

IgA nephropathy following vaccination in a renal transplant recipient with a history of aristolochic acid nephropathy: https://pubmed.ncbi.nlm.nih.gov/34816609/

IgA nephropathy in 2 pediatric patients after Pfizer (13 and 17yo): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8256683/

3 cases of IgA nephropathy patients developing exacerbations following mRNA vaccine:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166778/

2 cases of IgA nephropathy patients developing exacerbations following moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987498/

2 cases of IgA Nephropathy patients developing hematuria after Pfizer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329426/

Reactivation of IgA vasculitis following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260100/

Reactivation of IgA vasculitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34848431/

Case of IgA vasculitis following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34535924/

IgA vasculitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34509658/

IgA vasculitis with renal and skin involvement following vaccination: https://pubmed.ncbi.nlm.nih.gov/34779011/

Membranous nephropathy following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34419553/

Membranous nephropathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34332960/

**Other:**

Gross hematuria after mRNA vaccination in two patients with histological and clinical diagnosis of IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/34766415/

Gross hematuria after Moderna vaccination for COVID in 2 patients with IgA nephropathy: https://pubmed.ncbi.nlm.nih.gov/33771584/

Distinct glomerular disease after mRNA vaccination: A Vigibase analysis: https://pubmed.ncbi.nlm.nih.gov/34822875/

Renal Thrombotic Microangiopathy following Pfizer in a 35yoM: https://pubmed.ncbi.nlm.nih.gov/34451509/

Glomerulopathies after vaccination against covid-19: four cases with three different vaccines in Argentina: https://pubmed.ncbi.nlm.nih.gov/34728874/

**Rheumatology/Endocrinology/Orthopedics:**

**General:**

Cutaneous lupus erythematosus-like reaction following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35754159/

Hyper-inflammation after COVID-19 mRNA vaccination: at the cross roads of multi-inflammatory disease and adult onset still's disease https://pubmed.ncbi.nlm.nih.gov/34487678/

Immune mediated disease flares: https://pubmed.ncbi.nlm.nih.gov/33946748/

Local and systemic reactogenicity of Pfizer in patients with systemic lupus and rheumatoid arthritis: https://pubmed.ncbi.nlm.nih.gov/34476603/

Incidence of disease flare after Pfizer vaccination in patients with rheumatoid arthritis in remission: https://pubmed.ncbi.nlm.nih.gov/34472714/

11% of patients with rheumatic and MSK diseases report disease flare following 2 dose mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34346185/

**Macrophage Activation Syndrome:**

Macrophage activation syndrome in a patient with adult-onset Still's disease following first dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34961551/

**Still's Disease:**

Adult onset Still's disease following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34316728/

Adult onset Still's disease after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35186544/

Flare up of adult onset Still's disease in a 37yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34622765/

Adult onset Still's disease in a 43yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34763089/

Flare of adult onset still's disease following Pfizer in a 49yoF: https://pubmed.ncbi.nlm.nih.gov/35182269/

Still's disease in a 34yoF following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34797392/

Adult onset Still's disease in a 36yo following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34962116/

Adult onset Still's disease following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34316726/

**Lupus:**

New onset systemic lupus erythematosus beginning as class V lupus nephritis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34560139/

Lupus nephritis flare following Moderna: https://pubmed.ncbi.nlm.nih.gov/34791449/

Lupus exacerbation: https://onlinelibrary.wiley.com/doi/10.1111/dth.15017

New-onset systemic lupus erythematosus after AstraZeneca and alopecia areata after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35770484/

Lupus exacerbation following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34291477/

27 cases of lupus flare following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34782941/

New onset lupus following mRNA vaccination in a 27yoF: https://pubmed.ncbi.nlm.nih.gov/35186342/

Systemic lupus following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34418261/

Relapse of class V lupus. Nephritis after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34352310/

Subacute cutaneous lupus erythematosus flare triggered by Moderna: https://pubmed.ncbi.nlm.nih.gov/34455671/

Subacute cutaneous lupus erythematous after Pfizer in a woman with primary biliary cholangitis: https://pubmed.ncbi.nlm.nih.gov/34807495/

New onset lupus, pancreatitis, and vasculitic rash in a 22yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35175446/

Emergence of new onset SLE following vaccination: https://pubmed.ncbi.nlm.nih.gov/34450645/

**Hyperglycemic / Glucose:**

COVID-19 vaccine and hyperosmolar hyperglycemic state: https://pubmed.ncbi.nlm.nih.gov/33927933/

Acute Hyperglycemic crisis: a case series of 3 patients following AstraZeneca: https://onlinelibrary.wiley.com/doi/abs/10.1111/dme.14631

Newly developed type 1 diabetes after Moderna in a 73yoF: https://pubmed.ncbi.nlm.nih.gov/35088548/

3 cases of exacerbation of hyperglycemia in patients with type 2 diabetes following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8143905/

3 cases of hyperglycemic emergencies following Pfizer and Moderna: https://pubmed.ncbi.nlm.nih.gov/34604689/

Perturbation of blood glucose following vaccination, a review of 20 adults: https://pubmed.ncbi.nlm.nih.gov/34375490/

Hypertriglyceridemia following Pfizer vaccination in a patient with familial hypercholesteremia: https://pubmed.ncbi.nlm.nih.gov/34533798/

**Thyroid:**

Silent thyroiditis following Pfizer, subacute thyroiditis following moderna, and Graves disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34792795/

Subacute thyroiditis after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35095149/

SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review: https://pubmed.ncbi.nlm.nih.gov/35094372/

11 cases of COVID-19 vaccine induced subacute thyroiditis: https://pubmed.ncbi.nlm.nih.gov/35182366/

**Subacute Thyroiditis:**

https://www.tandfonline.com/doi/abs/10.1080/21645515.2021.1947102?fbclid=IwAR02FYW94iQGbu6e2uTpD42XoIwp6QHzwhDBWotULtT4ZCGR5sVKkyexbRg

Subacute thyroiditis following vaccination: https://pubmed.ncbi.nlm.nih.gov/34690055/

Subacute thyroiditis following Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34777881/

Subacute thyroiditis following Pfizer: a tale of two sisters: https://pubmed.ncbi.nlm.nih.gov/34686971/

Subacute thyroiditis associated thyrotoxic periodic paralysis in a 26yoF following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35578985/

42yoF with subacute thyroiditis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34907904/

Thyroiditis after mRNA vaccine: a case series: https://pubmed.ncbi.nlm.nih.gov/34934810/

Two cases of subacute thyroiditis after Moderna and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34504856/

4 cases of subacute thyroiditis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34893014/

Two cases of thyroiditis after Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34693241/

New onset Graves disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34888290/

Graves disease following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34969799/

Graves disease following mRNA COVID-19 vaccination: case series: https://pubmed.ncbi.nlm.nih.gov/34939881/

New onset Graves disease and autoimmune diabetes mellitus following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34653776/

Two cases of Graves disease following vaccination: https://pubmed.ncbi.nlm.nih.gov/33858208/

Two more cases of Graves disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34342859/

Hyperthyroidism following vaccination: https://pubmed.ncbi.nlm.nih.gov/34696214

Incidental findings on a TC99M-SESTAMIBI parathyroid scan post Moderna vaccination in a 48yoF: https://pubmed.ncbi.nlm.nih.gov/35535123/

**Adrenal:**

5 cases of adrenal crisis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34358373/

Myositis in a 56yoF following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/33647971/

COVID-19 vaccine induced cellulitis and myositis: https://pubmed.ncbi.nlm.nih.gov/34857596/

New onset giant cell arteritis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35112193/

2 cases of Löfgren's syndrome following AstraZeneca and Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34835244/

mRNA induced rhabdomyolysis and fasciitis: https://pubmed.ncbi.nlm.nih.gov/34435250/

Rhabdomyolysis after Moderna: https://pubmed.ncbi.nlm.nih.gov/34150372/

21yoM with Pfizer induced rhabdomyolysis: https://pubmed.ncbi.nlm.nih.gov/34186348/

**Inflammation / Arthritis:**

Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases: https://pubmed.ncbi.nlm.nih.gov/34836886/

Cubital tunnel syndrome temporally following Moderna in a 28yoF: https://pubmed.ncbi.nlm.nih.gov/35448837/

New-onset polymyalgia rheumatica in a 80yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34897152/

Polymyalgia rheumatica following covid-19 vaccination: a case series of ten patients: https://pubmed.ncbi.nlm.nih.gov/34954076/

Relapse of polymyalgia rheumatica in a 83yoM: https://pubmed.ncbi.nlm.nih.gov/33588357/

2 cases of polymyalgia rheumatica and 1 case of giant cell arteritis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34600148/

50yoM with clinical syndrome of HSP including IgA leukocytoclastic vasculitis on skin biopsy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34984055/

Quadrilateral space region inflammation and other incidental findings on shoulder MRI following Pfizer COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34306275/

Rash, arthritis, swelling, muscle weakness following AstraZeneca: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.27175

Self-limiting polymyalgia rheumatic-like syndrome following Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34980802/

Polyarthralgia and Myalgia syndrome after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34463066/

Severe polyarthralgia in elderly female following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34835151/

Arthritis in the L elbow following vaccination: https://pubmed.ncbi.nlm.nih.gov/34363344/

Vasculitis and bursitis on 18F FDG-PET/CT following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34495381/

Remitting seronegative symmetrical synovitis with pitting edema following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34348912/

COVID-19 vaccination and large0vessel giant cell arteritis: https://pubmed.ncbi.nlm.nih.gov/34788208/

**HSP:**

40yoF with Henoch-Schonlein Purpura (HSP) following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34247902/

45yoF with reactivation of HSP following Pfizer booster: https://pubmed.ncbi.nlm.nih.gov/34745629/

62yo with HSP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34518812/

76yoF with HSP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34696186/

**Psoriasis:**

New onset mainly guttate psoriasis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34309932/

2 cases of exacerbation of plaque psoriasis after Pfizer and CoronaVac: https://pubmed.ncbi.nlm.nih.gov/34427024/

Psoriatic spondyloarthritis exacerbation triggered by mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/35176180/

Psorasis exacerbation in a 46yoM after 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/34131967/

14 cases of psoriasis activation following vaccination (Moderna, Pfizer, and AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34363647/

Pustuluar psoriasis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34398977/

Psorasis exacerbation after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34487570/

Scleroderma renal crisis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34339745/

**Cryoglobulinaemia:**

Flares of mixed cryoglobulineamia vasculitis after vaccination https://ard.bmj.com/content/early/2021/11/23/annrheumdis-2021-221248.long

Pheochromocytoma crisis following J&J vaccination: https://pubmed.ncbi.nlm.nih.gov/34707965/

**Hematology**

Treatment Guide to Thrombotic Thrombocytopenia Following Vaccination: https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic-thrombocytopenia

Autoimmune post-COVID vaccine syndromes: does the spectrum of autoimmune/inflammatory syndrome expand? https://pubmed.ncbi.nlm.nih.gov/35378658/

Successful venous thromboprophylaxis in a patient with AstraZeneca induced VITT: https://pubmed.ncbi.nlm.nih.gov/34496889/

Coagulopathies after vaccination against SARS-COV-2 may be derived from a combo of spike protein and adenovirus vector-triggered signaling

pathways: https://arxiv.org/abs/2109.00089?fbclid=IwAR2orycgbxqSNXLR9A4XjNwEAZBumiRbRKsfW8KL5qiJCXSWwqmLiMtc4Z4

Arterial thrombosis in an unusual site (ulnar artery) in a 68yoM following 3rd dose of Moderna: https://pubmed.ncbi.nlm.nih.gov/35645305/

Autoimmunity roots of the thrombotic events following COVID vaccination: https://pubmed.ncbi.nlm.nih.gov/34508917/

Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways: https://pubmed.ncbi.nlm.nih.gov/34479129/

Changes in blood viscosity after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34868465/

Platelet activation and modulation in thrombosis with thrombocytopenia syndrome associated with AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34474550

The known knowns and known unknowns of vaccine-induced thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34472568/

Life-changing consequences of vaccine-induced immune-mediated thrombosis with thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34961923/

Coagulopathies after vaccination against SARS-COV-2 may be derived from a combo of spike protein and adenovirus vector-triggered signaling pathways: https://arxiv.org/abs/2109.00089?fbclid=IwAR2orycgbxqSNXLR9A4XjNwEAZBumiRbRKsfW8KL5qiJCXSWwqmLiMtc4Z4

Vaccine induced thrombocytopenia and thrombosis: venous endotheliopathy leading to venous combined micro-macrothrombosis: https://pubmed.ncbi.nlm.nih.gov/34833382/

The roles of platelets in COVID-19-associated coagulopathy and vaccine-induced immune thrombotic thrombocytopenia: https://pubmed.ncbi.nlm.nih.gov/34455073/

Safety warning for AstraZeneca in patients with sickle cell disease: https://mjhid.org/index.php/mjhid/article/view/4708?fbclid=IwAR2kMtsqqwiYyxxQ9XxIvDFdOSt-yTPqjAro-fgaEp460JeHd0QwBxx4DPg

**Hemolysis**

Post-COVID vaccination acute hemolysis in an older man: https://pubmed.ncbi.nlm.nih.gov/34821933/

Autoimmune hemolytic anemia: https://pubmed.ncbi.nlm.nih.gov/34150386/

First and fatal case of autoimmune acquired factor XIII/13 deficiency after Pfizer in a 78yoF: https://pubmed.ncbi.nlm.nih.gov/34856014/

Autoimmune hemolytic anemia following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34258873/

Autoimmune hemolytic anemia after Moderna with undetected pernicious anemia: https://pubmed.ncbi.nlm.nih.gov/35103106/

Cold agglutinin disease in a 45yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34176130/

Hemolytic crisis in a woman with cold agglutinin disease following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/33939851/

Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor following Moderna: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26262

6 Paraoxysmal nocturnal hemoglobinuria patients with hemolytic crisis following Pfizer and Moderna: https://ashpublications.org/blood/article/137/26/3670/475905/COVID-19-vaccines-induce-severe-hemolysis-in

**Anemia**

Aplastic anemia in a 56yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34920343/

Aplastic anemia after COVID vaccination: https://pubmed.ncbi.nlm.nih.gov/34783367/

**ITP**

ITP and AIHA following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274740/

95yoM with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35022338/

2 cases of ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35022337/

ITP Exacerbation in previous stable patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34307734/

ITP relapse post-Pfizer vaccine in a 28yoM: https://pubmed.ncbi.nlm.nih.gov/34804803/

ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34155844/

ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34382388/

ITP following booster dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34820240

ITP in a man in his mid 20s following Pfizer requiring splenectomy: https://pubmed.ncbi.nlm.nih.gov/35725277/

38yoF with ITP and myocarditis following Moderna: https://pubmed.ncbi.nlm.nih.gov/35638196/

Exacerbation of ITP following initial and booster dose of Pfizer, 93 patients: https://pubmed.ncbi.nlm.nih.gov/35536172/

Secondary ITP and resulting hemorrhage and hematoma after minor oral surgery after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34314875/

ITP and diffuse papular rash following Moderna: https://www.scienceopen.com/document_file/691feaa0-8e64-40c4-9553-40382bd5ac48/PubMedCentral/691feaa0-8e64-40c4-9553-40382bd5ac48.pdf

ITP following
Astrazeneca: https://ashpublications.org/blood/article/doi/10.1182/blood.2021012790/476455/Immune-Thrombocytopenic-Purpura-after-vaccination

ITP in 1st trimester of pregnancy 13 days following vaccination in the
US: https://pubmed.ncbi.nlm.nih.gov/34420249/

20yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34381692/

22yoM with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33476455/

24yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34754937/

25yoF with ITP exacerbation following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34660131/

26yoF with ITP and acute liver injury following Moderna: https://pubmed.ncbi.nlm.nih.gov/34330722/

26yoF with ITP following Moderna: http://pubs.sciepub.com/ajmcr/9/8/3/index.html

28yoM with ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/33934330/

37yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34732627/

39yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34285180/

41yoF with secondary ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34059544/

41yoM with ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34377889/

54yoF with ITP following Pfizer: https://www.cureus.com/articles/56899-newly-diagnosed-idiopathic-thrombocytopenia-post-covid-19-vaccine-administration

63yoF with ITP following Johnson and Johnson: https://pubmed.ncbi.nlm.nih.gov/34469919/

67yoF with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34513446/

68yoF with ITP in Korea following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34751013/

68yoF with ITP following Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385179/

69yoF with refractory ITP following
Pfizer: https://journals.lww.com/americantherapeutics/Citation/2021/08000/Immune_Thrombocytopenic_Purpura_Associated_With.24.aspx

74yoM with ITP following Moderna: https://www.dovepress.com/severe-refractory-immune-thrombocytopenia-occurring-after-sars-cov-2-v-peer-reviewed-fulltext-article-JBM

84yoM with ITP following Pfizer: https://link.springer.com/article/10.1007/s11739-021-02778-w

86yoM with ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34446449/

2 cases of ITP following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34114220/

3 cases of ITP following Pfizer and Astra Zeneca: https://www.mjhid.org/index.php/mjhid/article/view/4669/4043

3 cases reports of ITP following Pfizer and J&J: https://ehoonline.biomedcentral.com/articles/10.1186/s40164-021-00235-0

57yoF with myocarditis and hypopotassemia after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35430104/

74yoM with ITP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34077572/

Acquired hemophilia A in a 39yoF following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35211227/

69yoM with acquired hemophilia A after 2nd dose COVID vaccination: https://pubmed.ncbi.nlm.nih.gov/33783953/

Acquired hemophilia A in a 72yoM and concurrent diagnosis of pleomorphic dermal sarcoma following Moderna booster: https://pubmed.ncbi.nlm.nih.gov/35479071/

Acquired hemophilia A in a 72yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35379010/

Acquired hemophilia A and bullous pemphigoid in a 77yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/35321820/

Acquired hemophilia A in a man in his 80s after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35264381/

Acquired hemophilia A following Pfizer, successfully treated with prednisolone and rituximab: https://pubmed.ncbi.nlm.nih.gov/35088622/

4 cases of acquired hemophilia A after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35081484/

3 cases: recurrent AvWD and acquired hemophilia A after Moderna, PNH flare following Moderna, and ITP flare following Moderna: https://ashpublications.org/bloodadvances/article/5/13/2794/476324/Autoimmune-and-complement-mediated-hematologic

3 cases of acquired hemophilia A after mRNA vaccine, investigation into possible mechanism: https://pubmed.ncbi.nlm.nih.gov/35108443/

3 cases of ITP, 2 in chronic individuals and 1 in a healthy individual, following Pfizer and Moderna: https://pubmed.ncbi.nlm.nih.gov/34716890/

10 cases of ITP following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35108113/

3 cases of ITP in elderly patients following vaccination: https://www.hindawi.com/journals/crihem/2016/7913092/

4 cases of severe ITP following Pfizer, Moderna, and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34653943/

20 cases of ITP following Pfizer and Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/33606296/

21 cases of ITP following Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34756770/

36 Cases of ITP following Pfizer and Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011062/

77 denovo cases of ITP and 19 ITP exacerbation following vaccination: https://pubmed.ncbi.nlm.nih.gov/34587251/

12% of chronic ITP patients have exacerbation of ITP in 2-5 days following vaccination: https://pubmed.ncbi.nlm.nih.gov/34075578/

**Thrombolytic / Thrombocytopenia**

CoV-2 vaccination in patients with autoimmune cytopenias: the experience of a reference center: https://pubmed.ncbi.nlm.nih.gov/34478178/

PE, TIA, and thrombocytopenia after J&J: https://pubmed.ncbi.nlm.nih.gov/34261635/

Superior ophthalmic Vein Thrombosis and Thrombocytopenia following AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265377/

DVT and PE and positive HIT panel following mRNA Vaccine: https://pubmed.ncbi.nlm.nih.gov/34117206/

An unusual presentation of acute DVT after moderna vaccine: https://pubmed.ncbi.nlm.nih.gov/34790811/

3 patients with venous thromboembolism following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34352418/

Thrombosis with Thrombocytopenia following Moderna: https://www.acpjournals.org/doi/full/10.7326/L21-0244

34yoF with vaccine induced thrombotic thrombocytopenia following Moderna: https://pubmed.ncbi.nlm.nih.gov/34804389/

Thrombotic thrombocytopenia following Pfizer vaccination in a Japanese Patient: https://pubmed.ncbi.nlm.nih.gov/34803105/

Case report: vaccine-induced immune thrombotic thrombocytopenia in a pancreatic cancer patient after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34790684/

Case study of Thrombosis and Thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34781321/

Eltromopag for refractory vaccine-induced immune thrombotic thrombocytopenia in a 64yoF following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34797474/

TTP Following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34264514/

Acquired TTP following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34309715/

TTP in a 25yoM following Moderna: https://pubmed.ncbi.nlm.nih.gov/34895163/

Clinical relapse of immune mediated TTP in a 28yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35155977/

Denovo iTTP episode in a 38yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34105244/

Acquired TTP in a 61yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34909764/

Case series of patients who developed acquired TTP within several days of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34909764/

TTP in an adolescent following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34405400/

Flare of compensated congenital TTP following vaccination: https://pubmed.ncbi.nlm.nih.gov/34693915/

Thrombocytopenia in a teen with sickle cell disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34331506/

5 cases of prothrombotic immune thrombocytopenia after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34323939/

20 cases of Thrombocytopenia following Pfizer and Moderna: https://onlinelibrary.wiley.com/doi/10.1002/ajh.26132

Review of 50 cases of thrombocytopenia following Astrazeneca, Pfizer, Moderna: https://pubmed.ncbi.nlm.nih.gov/34332437/

68yoF with extensive thrombosis after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34400433/

Thrombotic Thrombocytopenia after AstraZeneca: Autopsy findings: https://pubmed.ncbi.nlm.nih.gov/34355379/

3 cases of adolescents with Pfizer induced TTP: https://pubmed.ncbi.nlm.nih.gov/35373880/

Fatal ICH due to Thrombotic Thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34402235/

Five cases with a combination of cerebral venous thrombosis, intracerebral hemorrhage and thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34393988/

**VITT**

Late Onset VITT with cerebral venous sinus thrombosis: https://pubmed.ncbi.nlm.nih.gov/35093626/

Confusion and abdominal pain due to VITT following vaccination: https://pubmed.ncbi.nlm.nih.gov/34346657/

Fatal thromboembolism in a patient with preexisting thrombocytopenia following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34344867/

Malignant CVA due to VITT following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34341358/

Anti-platelet factor 4 IgG levels in VITT: persistent positivity through 7 months: https://pubmed.ncbi.nlm.nih.gov/35515079/

Thrombosis patterns and clinical outcome of VITT: a systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/35339716/

Second dose VITT: rare but real: https://pubmed.ncbi.nlm.nih.gov/35482343/

Mechanisms of immunothrombosis in VITT compared to natural COVID infection: https://pubmed.ncbi.nlm.nih.gov/34051613/

3 cases of immune thrombocytopenia following AstraZeneca in Thailand: https://pubmed.ncbi.nlm.nih.gov/34483267/

**Other:**

New onset evans syndrome associated with systemic lupus erythematosus after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34687421/

Skin, nose, and gingival bleeding episodes after AstraZeneca: a large population-based cohort study: https://pubmed.ncbi.nlm.nih.gov/34479760/

Haemophagocytosis and atypical lymphocytes on bone marrow biopsy following vaccination: https://pubmed.ncbi.nlm.nih.gov/34312842/

Hemophagocytic lymphohistiocytosis (HLH) in a 14yoF requiring VA ECMO: https://pubmed.ncbi.nlm.nih.gov/35455321/

3 cases of HLH following AstraZeneca: https://jcp.bmj.com/content/early/2021/07/22/jclinpath-2021-207760

Idiopathic ipsilateral external jugular vein thrombophlebitis after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/33624509/

Possible risk of thrombotic events following AstraZeneca in women receiving estrogen: https://pubmed.ncbi.nlm.nih.gov/34734086/

Blood clots and bleeding events following Pfizer and AstraZeneca: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34174723/

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with AstraZeneca in Denmark and Norway: a population based cohort study: https://pubmed.ncbi.nlm.nih.gov/33952445/

Association of AstraZeneca and Pfizer with major venous, arterial, or thrombocytopenic events: a population based cohort study of 46 million adults in England: https://pubmed.ncbi.nlm.nih.gov/35192597/

Isolated thrombosis after COVID-19 vaccination: case series: https://pubmed.ncbi.nlm.nih.gov/34993889/

Arterial thrombosis following 1st dose AstraZeneca: a case series: https://pubmed.ncbi.nlm.nih.gov/35571586/

## Oncología:

**General**

Temporal metabolic response to mRNA vaccinations in oncology patients: https://pubmed.ncbi.nlm.nih.gov/34463888/

Coordination and optimization of FDG PET/CT and vaccination; lessons learned in the early stages of mass vaccination: https://pubmed.ncbi.nlm.nih.gov/34029956/

Post vaccination lymphadenopathy: report of cytological findings from fine needle aspiration biopsy: https://pubmed.ncbi.nlm.nih.gov/34432391/

Axillary lymphadenopathy after vaccination in a woman with breast cancer: https://pubmed.ncbi.nlm.nih.gov/34940788/

Fine needle aspiration in a vaccine associated lymphadenopathy: https://pubmed.ncbi.nlm.nih.gov/34286849/

Hypermetabolic lymphadenopathy following Pfier, incidence assessed by FDG PET-CT and revelance to study interpretation, a review of 728 vaccinated patients: https://pubmed.ncbi.nlm.nih.gov/33774684/

**Lymphadenopathy / Adenopathy:**

Lymphadenopathy following vaccination: imaging findings review: https://pubmed.ncbi.nlm.nih.gov/33985872/

Axillary lymphadenopathy following mRNA vaccination https://pubmed.ncbi.nlm.nih.gov/34156552/

Ipsilateral axillary adenopathy following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34333959/

Deep axillary lymphadenopathy after vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34694537/

Unilateral axillary lymphadenopathy following vaccination: a case report and imaging findings: https://pubmed.ncbi.nlm.nih.gov/33868525/

Unilateral axillary lymphadenopathy after vaccination: https://pubmed.ncbi.nlm.nih.gov/33617289/

Axillary adenopathy following vaccination, a new diagnostic dilemma: https://pubmed.ncbi.nlm.nih.gov/34825530/

Unilateral axillary adenopathy in the setting of covid-19 vaccine: https://pubmed.ncbi.nlm.nih.gov/33486146/

COVID-19 vaccination (Pfizer) simulating lymph node progression in a patient with prostate cancer: https://pubmed.ncbi.nlm.nih.gov/35747740/

Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a Moderna vaccine recipient: https://pubmed.ncbi.nlm.nih.gov/35748061/

COVID-19 vaccine induced subclinical axillary lymphadenopathy on screening mammogram: https://pubmed.ncbi.nlm.nih.gov/34906409/

Unilateral axillary adenopathy following vaccination: a multimodality pictorial illustration and review of current guidelines: https://pubmed.ncbi.nlm.nih.gov/34053731/

False positive axillary lymph nodes on FDG PET/CT resulting from covid-19 immunization: https://pubmed.ncbi.nlm.nih.gov/33883486/

4 cases of axillary adenopathy following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34303188/

COVID-19 vaccination associated axillary adenopathy: imaging findings and follow-up recommendations in 23 women: https://pubmed.ncbi.nlm.nih.gov/33624520/

163 cases of axillary adenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34257025/

mRNA vaccination: age and immune status and its association with axillar lymph node PET/CT uptake, a review of 426 patients: https://pubmed.ncbi.nlm.nih.gov/33893188/

Ipsilateral avid axillary lymph node update at FDG PET/CT persists in 29% of patients 7-10 weeks after 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/33904778/

Incidence of axillary adenopathy on Breast Imaging following Vaccination: https://pubmed.ncbi.nlm.nih.gov/34292295/

Breast radiation recall phenomena after AstraZeneca: A case series: https://pubmed.ncbi.nlm.nih.gov/35103229/

Regional lymphadenopathy following vaccination: literature review and considerations for patient management in breast cancer care: https://pubmed.ncbi.nlm.nih.gov/34731748/

Axillary lymphadenopathy at the time of vaccination: ten recommendations from the European society of breast imaging: https://pubmed.ncbi.nlm.nih.gov/34417642/

Evolving bilateral hypermetabolic axillary lymphadenopathy on FDG PET/CT following 2-dose COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34735411/

Axillary lymph nodes hypermetabolism after Pfizer in cancer patients underoing 18F-FDG PET/CT: a cohort study: https://pubmed.ncbi.nlm.nih.gov/33782299/

Reactive axillary lymphadenopathy to covid-19 vaccination on F-FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33820864/

Association of COVID-19 mRNA vaccine with ipsilateral axillary node reactivity on imaging: https://pubmed.ncbi.nlm.nih.gov/34110378/

Supraclavicular lymphadenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34414929/

Rare case of contralateral supraclavicular lymphadenopathy after vaccination: CT and ultrasound findings: https://pubmed.ncbi.nlm.nih.gov/34667486/

Supraclavicular lymphadenopathy after vaccination in Korea: a serial follow-up using ultrasonography: https://pubmed.ncbi.nlm.nih.gov/34116295/

Supraclavicular lymphadenopathy following vaccination: an increasing presentation to the two-week wait neck lump clinic? https://pubmed.ncbi.nlm.nih.gov/33685772/

Vaccination and low cervical lymphadenopathy in the two week neck lump clinic- a follow up audit: https://pubmed.ncbi.nlm.nih.gov/33947605/

Cervical lymphadenopathy following Pfizer https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204135/

13 cases of Cervical lymphadenopathy: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241354/

50yoM with adenopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34406229/

Review of 24 cases of lymphadenopathy and their ultrasound findings in the US: https://pubmed.ncbi.nlm.nih.gov/34356507/

Kikucki-Fujimoto disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34395192/

2 cases of Kikuchi-Fujimoto Disease following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34835182/

Mammographic and sonographic findings in the breast and axillary tail following vaccination: https://pubmed.ncbi.nlm.nih.gov/34340203/

Management of unilateral axillary lymphadenopathy detected on breast MRI in the era of covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33543649/

Mitigating the impact of COVID-19 vaccinations on patients undergoing breast imaging examinations: a pragmatic approach: https://pubmed.ncbi.nlm.nih.gov/33617288/

COVID-19 vaccine related axillary and cervical lymphadenopathy in patients with current or prior breast cancer and other malignancies: cross sectional imaging findings on MRI, CT, and PET-CT: https://pubmed.ncbi.nlm.nih.gov/34719892/

The challenge of staging breast cancer with PET/CT in the era of covid vaccination: https://pubmed.ncbi.nlm.nih.gov/33795590/

Vaccination and breast cancer surgery timing: https://pubmed.ncbi.nlm.nih.gov/34156582/

Vaccine related unilateral axillary lymphadenopathy: pattern on screening breast MRI: https://pubmed.ncbi.nlm.nih.gov/34325221/

Evolution of lymphadenopathy at PET/MRI after vaccination: https://pubmed.ncbi.nlm.nih.gov/34310229/

Axillary lymphadenopathy after COVID vaccination in patients with thoracic malignancy: https://pubmed.ncbi.nlm.nih.gov/34506955/

DOTATATE PET-avid axillary lymph node after injection of the Johnson & Johnson: https://pubmed.ncbi.nlm.nih.gov/34269723

DOTATATE-avid bilateral axillar and subpectoral lymphadenopathy induced from mRNA vaccination visualized on PET/CT: https://pubmed.ncbi.nlm.nih.gov/33795589/

DOTATOC-avid lymphadenopathies induced by mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34363083/

3 cases of supraclavicular and axillary lymphadenopathy induced by vaccination on 18F-Fluorthanatrace, 68Ga-DOTATATE, and 18F-Fluciclovine PET/CT: https://pubmed.ncbi.nlm.nih.gov/34507331/

FDG uptake in axillary lymph nodes after vaccination: a pitfall case of highly suspicious lymph nodes metastases of malignant melanoma: https://pubmed.ncbi.nlm.nih.gov/34412144/

Moderna vaccination mimicking lymph-node progression in a patient with melanoma: https://pubmed.ncbi.nlm.nih.gov/34433198/

COVID-19 vaccine as cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma: https://pubmed.ncbi.nlm.nih.gov/33675368/

Pfizer vaccination manifesting as incidental lymph node uptake on 18F-FDG PET/CT in a melanoma patient: https://pubmed.ncbi.nlm.nih.gov/33661193/

Axillary adenopathy following AstraZeneca resulting in possible misinterpretation of PET scan in metastatic melanoma patient: https://pubmed.ncbi.nlm.nih.gov/34414110/

8 patients where mRNA vaccine mimics lymph node metastates in patients undergoing skin cancer follow-up: https://pubmed.ncbi.nlm.nih.gov/34280870/

Hypermetabolic reactive lymphadenopathy following 3rd COVID-19 vaccination in a breast cancer patient and a patient with squamous cell carcinoma of the head and neck: https://pubmed.ncbi.nlm.nih.gov/34746900/

False Positive FDG PET CT after vaccination in a woman treated for metastatic breast cancer: https://pubmed.ncbi.nlm.nih.gov/34308402/

COVID-19 vaccine related axillary lymphadenopathy in breast cancer patients: case series with a review of the literature: https://pubmed.ncbi.nlm.nih.gov/34836672/

Pfizer vaccine related local FDG uptake in a lymphoma patient: https://pubmed.ncbi.nlm.nih.gov/33661194/

mRNA vaccination induced lymphadenopathy mimics lymphoma progression on FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33591026/

Avid left axillary nodes and intense diffuse splenic uptake and moderate diffuse bone marrow uptake on PET 1 week after vaccination: https://pubmed.ncbi.nlm.nih.gov/34269722/

Limiting screening mammography recalls for vaccine-induced adenopathy, a single institution experience: https://pubmed.ncbi.nlm.nih.gov/35090829/

**FDG-PET / PET-CT findings:**

Vaccination effect on tracer uptake with FDG-PET/CT: https://pubmed.ncbi.nlm.nih.gov/34297113/

18-FDG-Avid lymph nodes after covid-19 vaccination on PET/CT: https://pubmed.ncbi.nlm.nih.gov/33782318/

18-FDG-Avid lymph nodes after covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33741644/

FDG update in axillary lymph nodes and deltoid muscle after mRNA vaccination: a cohort study to determine incidence and contributing factors using a multivariate analysis: https://pubmed.ncbi.nlm.nih.gov/35098436/

COVID-19 vaccination induced axillary nodal update on 18F FDG PET/CT: https://pubmed.ncbi.nlm.nih.gov/33638003/

Prevelance and significance of hypermetabolic lymph nodes detected by 18F FDG PET/CT after vaccination: a systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34451859/

AstraZeneca vaccination included lymphadenopathy on 18F choline PET/CT-not only an FDG finding: https://pubmed.ncbi.nlm.nih.gov/33661328/

Abnormal PET following vaccination: https://onlinelibrary.wiley.com/doi/full/10.1002/pbc.29262

Positive PET following vaccination: https://pubmed.ncbi.nlm.nih.gov/34301777/

Vaccine related lymph node activation-patterns of uptake on PET CT: https://pubmed.ncbi.nlm.nih.gov/34131510/

Lymphadenopathy in vaccine recipients: a diagnostic dilemma in oncologic patients: https://pubmed.ncbi.nlm.nih.gov/33625300/

The day after mass COVID vaccination: higher hypermetabolic lymphadenopathy detection on PET/CT and impact on oncologic management: https://pubmed.ncbi.nlm.nih.gov/34503150/

Frequency and characteristics of nodal and deltoid FDG and C-Choline update on PET performed after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34009000/

COVID-19 vaccination-related update on FDG PET/CT: an emerging dilemma and suggestions for management: https://pubmed.ncbi.nlm.nih.gov/33646823/

Subcutaneous uptake on 18F PET/CT: a case report of possible amyloid-beta immune-reactivity after vaccination: https://pubmed.ncbi.nlm.nih.gov/34541458/

Rapid progression of Angioimmunoblastic t cell lymphoma following Pfizer Booster: https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/full?fbclid=IwAR3N-pwv8MMsjpNgb3DeEQQ5GYEGmYBQDVveSbHXvg_y5kLHDYw_2EgNsns

**Lymphoma**

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report https://www.frontiersin.org/articles/10.3389/fmed.2021.798095/full

**Other:**

Thymic hyperplasia after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34462647/

Fatal systemic capillary leak syndrome after Johnson and Johnson vaccination in a multiple myeloma patient: https://pubmed.ncbi.nlm.nih.gov/34459725/

Rituximab-induced acute lympholysis and pancytopenia after Moderna in a 71yoM with b-cell lymphoplasmacytic lymphoma: https://pubmed.ncbi.nlm.nih.gov/34429981/

Systemic capillary leak syndrome in a middle age woman following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35292552/

Adverse reactions following vaccination in patients with cancer undergoing treatment: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527840/

Rapid development of radiation recall pneumonitis in a non-small cell lung cancer patient immediately following second dose of Moderna: https://pubmed.ncbi.nlm.nih.gov/33968515/

Radiation recall pneumonitis on FDG/ PET/CT triggered by mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34739397/

Radiation recall pneumonitis in a non-small cell lung cancer patient following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34791816/

**Dermatology/Plastics:**

2 cases of denovo dermatomyositis and inflammatory myositis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35094715/

Acute, ulcerative, sarcoidal tattoo reaction in a 38yoF following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35499440/

Eosinophilic cellulitis following Pfizer in a 12yoM: https://pubmed.ncbi.nlm.nih.gov/35522122/

Pemphigus vulgaris in a 60yoF following 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35278817/

A severe case of trichophyton rubrum-caused dermatomycosis exacerbated after Pfizer in a 75yoM: https://pubmed.ncbi.nlm.nih.gov/35299937/

Haemorrhagic bullous pyoderma gangrenosum in a 46yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35398933/

Pemphigus vulgaris in a 44yoM following 2nd dose AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35348281/

Morbilliform rash in a 30yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33560802/

6 cases of pityriasis rosea following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35698860/

Pityriasis rosea associated with covid-19 vaccination: a common rash following administration of a novel vaccine: https://pubmed.ncbi.nlm.nih.gov/35167784/

23yoF with pityriasis rosea-like rash after Pfizer: a case report and review of the literature: https://pubmed.ncbi.nlm.nih.gov/35156062/

40yoM with pityriasis rosea-like eruptions following Modera: a case report and literature review: https://pubmed.ncbi.nlm.nih.gov/35012825/

52yoF with pityriasis rosea-like eruption after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34557507/

53yoF with pityriasis rosea-like cutaneous eruption after AstraZenca: https://pubmed.ncbi.nlm.nih.gov/34533265/

56yoF with inverse pityriasis rosea after J&J: https://pubmed.ncbi.nlm.nih.gov/35518792/

Dermatomyositis-like rash and inflammatory myopathy after Moderna: https://pubmed.ncbi.nlm.nih.gov/35048951/

Dermatomyositis following Pfizer vaccination in a 43yoF: https://pubmed.ncbi.nlm.nih.gov/35132838/

Unilateral linear purpuric rash heralding AstraZeneca induced ITP: https://pubmed.ncbi.nlm.nih.gov/35176191/

60yo with Steven Johnson Syndrome: https://pubmed.ncbi.nlm.nih.gov/34081806/

Steven Johnson Syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34384729/

**Pemphigus Vulgaris**

Pemphigus vulgaris after COVID-19 vaccination: one new onset and two cases with severe aggravation: https://pubmed.ncbi.nlm.nih.gov/35187768/

An unusual presentation of pemphigus foliaceus following vaccination: https://pubmed.ncbi.nlm.nih.gov/34817063/

A case of erythroderma with elevated serum immunoglobulin E and thymus and activation-regulated chemokine levels following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34821411/

Spontaneous urticaria after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34692313/

Pityriasis-rosea like eruption post-vaccination in a young male: https://pubmed.ncbi.nlm.nih.gov/34165237

Pityriasis rosea, pityriasis rosea-like eruptions and herpes zoster after covid-19 and covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35093476/

Pityriasis rosea following Pfizer: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17498

Pityriasis lichenoides et varioliformis acuta after SARS-CoV2 infection a relapse after vaccination: https://pubmed.ncbi.nlm.nih.gov/35184341/

19yoM with Pityriasis rosea following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34374333/

29yoM with Pityriasis rosea after Moderna: https://pubmed.ncbi.nlm.nih.gov/34740803/

35yoM with Pityriasis rosea-like eruption after Pfizer: https://pubmed.ncbi.nlm.nih.gov/33904157/

40yoM with Pityriasis rosea after Moderna: https://pubmed.ncbi.nlm.nih.gov/34110010/

66yoM with Pityriasis rosea after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34435935/

1 case of Pityriasis rosea and 3 cases of urticaria following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34478204/

2 cases of Pityriasis rosea-like eruptions following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33982814/

Pityriasis rosea following Moderna vaccination, a case series: https://pubmed.ncbi.nlm.nih.gov/34816549/

Vaccine induced Pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature: https://pubmed.ncbi.nlm.nih.gov/25545307/

Ezematiform eruption after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34272069/

Two cases of papulo-pustular rosacea-like eruptions following Pfizer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416044/

Pityriasis rubra pilaris following Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34310778/

Pityriasis rubra pilaris in 72yoM following Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34420983/

Pityriasis Rubra Pilaris like eruption following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34379821/

Lymphomatoid drug reaction developed after Pfizer vaccine manifesting as pityriasis lichenoides et varioliformis acuta-like eruption: https://pubmed.ncbi.nlm.nih.gov/34751995/

Lichenoid drug eruption following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35097176/

Lichenoid drug eruption after COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34961975/

3 cases of new onset acral hand lesions following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34310777/

2 patients with eczematous cutaneous reactions following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236729/

Case study of 19 patients with cutaneous adverse reactions following vaccination: https://pubmed.ncbi.nlm.nih.gov/34698094/

New onset synovitis and palmoplantar psoriasis flare up after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236728/

Exacerbation of Hailey-Hailey Disease following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34436620/

New onset lichen planus following Pfizer: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17504

COVID-vaccine induced lichen planus on areas previously affected by vitiligo: https://onlinelibrary.wiley.com/doi/10.1111/jdv.17687

Lichen striatus: https://pubmed.ncbi.nlm.nih.gov/34423105/

46yoM with lichen planus eruption following AstraZeneca: a case report and review of literature: https://pubmed.ncbi.nlm.nih.gov/35386174/

Linear IgA bullous dermatosis following AstraZeneca in a 61yoM: https://pubmed.ncbi.nlm.nih.gov/34762342/

60yoF with vitiligo after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35393710/

Persistent pruritic morbilliform rash after 2nd dose Pfizer in a 59yoM: https://pubmed.ncbi.nlm.nih.gov/35199304/

Lichen planus flare following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34934493/

Purpura annularis telangiectodes following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34236717/

Flagellate Purpura following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34416052/

Pigmented purpuric dermatosis after Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34791786/

Symmetrical drug related intertriginous and flexural exanthema like eruption following AztraZeneca: https://pubmed.ncbi.nlm.nih.gov/34399001/

Vitiligo following Pfizer: https://onlinelibrary.wiley.com/doi/10.1111/ced.14842

Vitiligo in a Ulcerative Colitis Patient following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34498300/

Bacillus Calmette-Guerin scar flare after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34344774/

Palms and Soles Itchiness following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34391695/

Resistant pruritis skin rash following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34358176/

Morphea (70yoF) after AstraZeneca and a second patient after COVID-19 infection: https://pubmed.ncbi.nlm.nih.gov/35449768/

Necrotic eschars at injection sites one week after 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34337117/

Acral hemorrhage after second dose of vaccination: https://pubmed.ncbi.nlm.nih.gov/34697597/

Facial Pustular Neutrophilic Eruption following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34319363/

Acute generalized exanthematous pustulosis induced by Moderna: https://pubmed.ncbi.nlm.nih.gov/34466640/

AstraZeneca induced acute localized exanthematous pustulosis: https://pubmed.ncbi.nlm.nih.gov/34487574/

Delayed local skin reactions: https://www.nejm.org/doi/full/10.1056/NEJMc2102131?fbclid=IwAR0P6wjXiO4swT4wz0lEJCBx7v14e2Si-O9AbOuhlVisVHFhc_kGEy7pyj0

Delayed skin reactions following mRNA vaccine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288253/

11 patients with delayed skin reaction after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34433495/

Additional 12 Patients with Delayed Local Reactions: https://www.nejm.org/doi/full/10.1056/NEJMc2102131

16 patients delayed hypersensitivity reactions after Moderna: https://pubmed.ncbi.nlm.nih.gov/33978670/

138 Delayed Hypersensitivity Reactions following vaccination: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294276/

Delayed local Hypersensitivity reactions: a 6 month retrospective study: https://pubmed.ncbi.nlm.nih.gov/34288056/

Delayed cutaneous adverse reaction to AstraZeneca in a breastfed female infant: coincidence or rare effect?: https://pubmed.ncbi.nlm.nih.gov/35455352/

Delayed cutaneous hypersensitivity reaction following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34351606/

Cutaneous skin manifestation following Moderna with Hypersensitivity reaction Histopathology: https://pubmed.ncbi.nlm.nih.gov/34414254/

Assessment of delayed large local reactions after 1st dose of mRNA vaccine in Japan: https://pubmed.ncbi.nlm.nih.gov/35649530/

2 cases of delayed local reactions following Moderna: https://journals.lww.com/infectdis/Fulltext/2021/07000/Delayed_Skin_Rash_After_Receiving_SARS_CoV_2_mRNA.19.aspx

4 cases of cutaneous hypersensitivity reactions following Moderna: https://pubmed.ncbi.nlm.nih.gov/34485656

5 Japanese cases of delayed large local reactions to Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34459023/

13 cases delayed local reactions following mRNA vaccine: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab518/6291929

COVID Vaccine arm: https://www.psychologytoday.com/us/blog/heal-the-mind-heal-the-body/202101/what-s-the-new-phenomenon-called-covid-vaccine-arm

COVID arm following Moderna: histologic features: https://pubmed.ncbi.nlm.nih.gov/34242422/

COVID arm following Moderna detected by MR neurography: https://pubmed.ncbi.nlm.nih.gov/34746453/

Covid vaccine arm may present after both mRNA vaccines vaccination: https://pubmed.ncbi.nlm.nih.gov/34416053/

405 cases of dermatologic reactions following Pfizer, Moderna, and Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34254291/

Erythema Migrans like rash after Moderna: https://pubmed.ncbi.nlm.nih.gov/34250736/

Bullous neutrophilic dermatosis with severe acral oedema post mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35092306

Bullous pemphigoid after 2nd dose Pfixer in a 78yoM: https://pubmed.ncbi.nlm.nih.gov/35251600/

Bullous pemphigoid associated with covid-19 vaccines: an Italian multicentre study: https://pubmed.ncbi.nlm.nih.gov/35295599/

Bullous Drug Eruption Rash following Moderna: https://pubmed.ncbi.nlm.nih.gov/34294590/

Bullous eruption following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34416058/

Bullous Fixed Drug Eruption following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34482558/

Bullous pemphigoid triggered by covid-19 vaccine (Pfizer): rapid resolution with corticosteroid therapy: https://pubmed.ncbi.nlm.nih.gov/34786801/

Atypical erythema multiforme related to Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/34473839/

Erythema multiforme after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34962029/

Erythema multiforme reactions after Moderna and Pfizer: a case series: https://pubmed.ncbi.nlm.nih.gov/35097177/

Generalized erythema multiforme like rash following Pfizer in a 78yoM: https://pubmed.ncbi.nlm.nih.gov/34661942/

A flare up of pre-existing erythema multiforme following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33914926/

Prompt onset of Rowell's syndrome following 1st dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/33725406/

Annular plaques mimicking Rowell's syndrome following mRNA vaccines: an overlooked phenomenon? https://pubmed.ncbi.nlm.nih.gov/34693548/

4 cases of oral erythema multiforme after Pfizer (15, 55, 49, and 20yo): https://pubmed.ncbi.nlm.nih.gov/35331228/

Cutaneous adverse events related to COVID-19 vaccines: a cross-sectional questionnaire-based study of 867 patients: https://pubmed.ncbi.nlm.nih.gov/34820975/

Cutaneous reactions to covid-19 vaccine at dermatology primary care (21 patients): https://pubmed.ncbi.nlm.nih.gov/34837354/

Soft Tissue Filler Inflammatory Reaction after vaccination https://pubmed.ncbi.nlm.nih.gov/34174156/

Clinical and pathologic correlation of cutaneous covid-19 vaccine reactions including V-REPP: a registry-based study: https://pubmed.ncbi.nlm.nih.gov/34517079/

Cutaneous complications of mRNA and AstraZeneca vaccines: a worldwide review: https://pubmed.ncbi.nlm.nih.gov/35336199/

COVID related cutaneous manifestations: a systematic review: https://pubmed.ncbi.nlm.nih.gov/35141881/

A systematic review on mucocutaneous presentation after vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders: https://pubmed.ncbi.nlm.nih.gov/35316551/

New onset leukocytoclastic vasculitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33928638/

Erythema multiforme following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34676438/

Cutaneous adverse reactions associated with COV-2 vaccines: https://pubmed.ncbi.nlm.nih.gov/34830627/

Cutaneous adverse events related to COVID-19 vaccines: a cross-sectional questionnaire-based study of 867 patients: https://pubmed.ncbi.nlm.nih.gov/34820975/

Soft Tissue Filler Inflammatory Reaction after vaccination: https://pubmed.ncbi.nlm.nih.gov/34174156/

;Immune Response to fillers and breast implants after vaccination: https://pubmed.ncbi.nlm.nih.gov/34174765/

Breast Implant seroma after mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34405902/

L Breast Implant Capsular Contracture following Moderna vaccination: https://pubmed.ncbi.nlm.nih.gov/34373851/

COVID-toes after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34162525/

Systemic vasculitis in an 80yoM following mRNA vaccination demonstrated on FDG/PET: https://pubmed.ncbi.nlm.nih.gov/35175942/

2 cases of Vitiligo triggered by COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35145806/

Bacillus Calmette-Guerin scar erythema in a 14yoF post Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/35175660/

Leukocytoclastic vasculitis: https://onlinelibrary.wiley.com/doi/abs/10.1002/art.4191

Schnitzler syndrome after covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35650133/

Urticarial vasculitis after covid-19 vaccination: a case report and literature review: https://pubmed.ncbi.nlm.nih.gov/35652448/

Eosinophilic granulomatosis with polyangiitis in an elderly female following 2nd dose Moderna: https://pubmed.ncbi.nlm.nih.gov/35165624/

Generalized papulovesicular eruption as a side effect of Pfizer vaccine: https://pubmed.ncbi.nlm.nih.gov/35371700/

New onset leukocytoclastic vasculitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/33928638/

Leukocytoclastic vasculitis after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35099065/

Leukocytoclastic vasculitis flare following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33928638/

Leukocytoclastic vasculitis in a 42yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34196469/

Leukocytoclastic vasculitis after Pfizer vaccine booster: https://pubmed.ncbi.nlm.nih.gov/34720009/

Leukocytoclastic vasculitis in a 68yoF following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34713472/

Cutaneous leukocytoclastic vasculitis induction following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34853744/

Cutaneous vasculitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34611627/

Cutaneous vasculitis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34599716/

Leukocytoclastic vasculitis as a cutaneous manifestation of the AstraZeneca vaccine: https://pubmed.ncbi.nlm.nih.gov/34546608/

Leukocytoclastic vasculitis after exposure to AstraZeneca vaccine: https://pubmed.ncbi.nlm.nih.gov/34836739/

Urticarial Vasculitis following vaccination: https://journals.lww.com/amjdermatopathology/Citation/9000/Unique_Case_of_Urticarial_Skin_Eruptions_After.97698.aspx

Urticarial Vasculitis: https://pubmed.ncbi.nlm.nih.gov/34369046/

Small vessel vasculitis after Astra Zeneca: https://pubmed.ncbi.nlm.nih.gov/34310763/

Sweet-like syndrome and multiple covid-arm syndrome following covid-19 vaccine: specific patterns in a series of 192 patients: https://pubmed.ncbi.nlm.nih.gov/35653233/

Acute Posterior multifocal placoid pigment epitheliopathy after Pfizer in a 17yoM: https://pubmed.ncbi.nlm.nih.gov/35412479/

Possible case of mRNA vaccine induced small vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34705320/

Cutaneous small vessel vasculitis following J&J: https://pubmed.ncbi.nlm.nih.gov/34337124/

Cutaneous lymphocytic vasculitis following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34327795/

Pfizer induced reactivation of varicella and resulting small vessel vasculitis: https://pubmed.ncbi.nlm.nih.gov/34310759/

Granulomatous vasculitis after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34237323/

Immune complex vasculitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34530771/

Relapse of microscopic polyangiitis after Pfizer vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34251683/

De novo vasculitis after Moderna: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166777/

2 cases of skin color discoloration following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34310755/

A case series of rare cutaneous adverse events following vaccination: https://pubmed.ncbi.nlm.nih.gov/34363637/

Moderna Vaccine Induced Skin Rash: https://pubmed.ncbi.nlm.nih.gov/34423142/

A Case series of Cutaneous vaccine reactions at Loma Linda University: https://pubmed.ncbi.nlm.nih.gov/34423106/

Reactivation of BCH vaccination scars after vaccination with mRNA vaccines: https://pubmed.ncbi.nlm.nih.gov/34930152/

Clinicopathological features of cutaneous reactions after mRNA vaccines, 11 cases: https://pubmed.ncbi.nlm.nih.gov/34459036/

3 cases of vesiculobullous non-IgE-mediated cutaneous reactions to Pfizer: https://pubmed.ncbi.nlm.nih.gov/34363258/

Sweet Syndrome following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34835143/

A case of generalized sweet's syndrome with vasculitis triggered by J&J vaccination: https://pubmed.ncbi.nlm.nih.gov/34849386/

Bullous sweet syndrome following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34817862/

A narrative review of cutaneous and hypersensitivity reactions: https://pubmed.ncbi.nlm.nih.gov/34424434/

Clinical and histopathological spectrum of delayed adverse cutaneous reactions following covid-19 vaccination, a review of 12 cases: https://pubmed.ncbi.nlm.nih.gov/34292611/

SARS-CoV-2 Vaccines and the Skin: https://pubmed.ncbi.nlm.nih.gov/34483343/

COVID-19 vaccines and cutaneous adverse reactions; a review: https://pubmed.ncbi.nlm.nih.gov/33851937/

COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide: https://pubmed.ncbi.nlm.nih.gov/34556254/

Cutaneous reactions reported after Moderna and Pfizer vaccination: a registry based study of 414 cases: https://pubmed.ncbi.nlm.nih.gov/33838206/

Response to McManon et al's…414 cases: https://pubmed.ncbi.nlm.nih.gov/34801633/

Cutaneous findings following COVID019 vaccination: review of world literature and own experience: https://pubmed.ncbi.nlm.nih.gov/34661927/

Cutaneous and allergic reactions due to covid-19 vaccinations review: https://pubmed.ncbi.nlm.nih.gov/34791757/

Skin reactions to covid-19 vaccines: an AAD/ILDS registry update on reaction location and COVID vaccine type: https://pubmed.ncbi.nlm.nih.gov/34800601/

Alopecia areata following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35107173/

Alopecia areata in a 31yoM following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/35223675/

Alopecia areata in a 61yoF after 2nd dose Pfizer: https://pubmed.ncbi.nlm.nih.gov/35571458/

3 cases of recurrence of alopecia areta after Pfizer and AstraZeneca in Italy: https://pubmed.ncbi.nlm.nih.gov/34741583/

9 cases of alopecia areata after covid vaccination: https://pubmed.ncbi.nlm.nih.gov/34931171/

The role of COVID infection and its vaccine in various types of hair loss: https://pubmed.ncbi.nlm.nih.gov/35266262/

## Oftalmologia:

**General**

COVID-19, COVID-19 vaccinations, and subsequent abnormalities in the retina: causation or coincidence? https://pubmed.ncbi.nlm.nih.gov/34473193/

After the storm: ophthalmic manifestations of COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34826968/

Ocular adverse events after covid-19 vaccinations: https://pubmed.ncbi.nlm.nih.gov/34559576/

Bilateral acute posterior multifocal placoid pigment epitheliopathy (APMPPE) following mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/35750434/

Ocular manifestations after receiving COVID-19 vaccine: a systematic review: https://pubmed.ncbi.nlm.nih.gov/34960150/

Ocular adverse reactions: a review and update: https://pubmed.ncbi.nlm.nih.gov/33865883/

Ocular inflammatory events following COVID-19 vaccination: a multinational case series: https://pubmed.ncbi.nlm.nih.gov/34982290/

**Macular Neuroretinopathy:**

Acute Macular Neuroretinopathy after AstraZeneca https://www.nature.com/articles/s41433-021-01610-1.epdf?fbclid=IwAR1HGawxew4SJMoHonmJsMWpWh7Fdkh29191M84BsINLsNtOYj_R6oWqrTE

Acute macular neuroretinopathy following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34485760/

Central serous chorioretinopathy following Pfizer (38yoM military physician): https://pubmed.ncbi.nlm.nih.gov/34949501/

4 cases of serous chorioretinopathy following Pfizer (35-65yo): https://pubmed.ncbi.nlm.nih.gov/35577701/

Bilateral multifocal central serous retinopathy following Pfizer in a 32yoF: https://pubmed.ncbi.nlm.nih.gov/35599048/

Acute Central Serous Retinopathy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34151047/

Bilateral panuveitis mimicking vogt-koyanagi-harada disease following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35113750/

Panuveitis: https://pubmed.ncbi.nlm.nih.gov/34213988/

42 cases of Uveitis and other ocular complications following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34945256/

Reduction of Visual Acuity following Pfizer: https://link.springer.com/article/10.1007/s00011-021-01476-9?fbclid=IwAR3zAvenOwPAZmuVsx9CM7bFwOliHerfJK3M3nQCMe-3BWoT4QdNCWK7cNo

**Corneal Graft Rejection:**

Corneal graft rejection after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34426655/

Corneal graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34835205/

Acute corneal graft endothelial graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34281760/

Full thickness corneal transplant rejection 3 days following Moderna: https://pubmed.ncbi.nlm.nih.gov/34690266/

2 cases of corneal graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33910885

2 cases of corneal graft rejection following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34029238/

4 cases of Corneal graft rejection following Moderna: https://pubmed.ncbi.nlm.nih.gov/34620770/

Corneal graft rejection following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34827040/

Retinal vein occlusion following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35113504/

Combined central retinal artery and vein occlusion with ischemic optic neuropathy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/35079224/

Central retinal artery occlusion after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35088861/

Bilateral Retinal Detachments 10 days after mRNA vaccination 22yoF : https://www.jem-journal.com/article/S0736-4679(21)00611-9/fulltext

Retinal venous occlusion in a 28yoM after 3rd dose of AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35648014/

Exacerbation of branch retinal vein occlusion post Pfizer: https://pubmed.ncbi.nlm.nih.gov/34918688/

CMV reactivation and pericarditis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35116025/

**Vein Occlusion / Retinal Necrosis**

6 cases of retinal vascular events following Pfizer, Moderna, AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34835280/

Central Retinal Vein Occlusion occurring immediately after 2nd dose of mRNA vaccine: https://pubmed.ncbi.nlm.nih.gov/34426861/

Central vein occlusion after mRNA vaccination: a case report: https://pubmed.ncbi.nlm.nih.gov/34571653/

Combined central retinal artery and vein occlusion shortly after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34791479/

Acute retinal necrosis associated with reactivation of varicella zoster virus after Pfizer vaccination in 78yoM: https://pubmed.ncbi.nlm.nih.gov/34802376/

Acute retinal necrosis associated with reactivation of varicella zoster virus after Pfizer vaccination in 62yoM: https://pubmed.ncbi.nlm.nih.gov/34851795/

Acute retinal necrosis associated with reactivation of varicella zoster virus after Pfizer vaccination in 71yoM: https://pubmed.ncbi.nlm.nih.gov/34541931/

**Oculomotor Palsy**

Transient Oculomotor palsy following mRNA. Vaccine: https://pubmed.ncbi.nlm.nih.gov/34369471/

**Anterior Uveitis**

Anterior Uveitis following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34289406/

21 cases of Uveitis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34369440/

**Optic Neuropathy**

A case of bilateral arteritic anterior ischemic optic neuropathy and a case of bilateral acute zonal occult outer retinopathy after mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34394876/

**Herpes Keratitis**

Reactivation of herpes simplex keratitis following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34493563/

Relapse of stromal herpes keratitis following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34823340/

2 cases of Ipsilateral zoster opthalmicus after Moderna and Johnson and Johnson: https://pubmed.ncbi.nlm.nih.gov/34471577/

2 cases of herpes zoster ophthalmicus following vaccination: https://pubmed.ncbi.nlm.nih.gov/34690265/

Bilateral immune mediated keratolysis following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34483273/

**Other:**

Vaccination and Bilateral Multifocal Choroiditis: https://pubmed.ncbi.nlm.nih.gov/34406890/

34yoM with bilateral multifocal choroiditis following 2nd dose vaccination: https://pubmed.ncbi.nlm.nih.gov/34344280/

Acute painless bilateral blurring of vision following Pfizer due to Vogt-Koyanagi-Hara disease: https://pubmed.ncbi.nlm.nih.gov/34505819/

Multimodal Imaging of acute foveolitis following COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34797736/

Eyelid erythema after Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/34426009/

Transient eyelid edema following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34524252/

Disc edema in one eye and central serous chorioretinopathy in the other following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34783448/

## Oido, Nariz, Garganta

Persisting, unilateral tinnitus after mRNA vaccine: https://journals.lww.com/jfmpc/Fulltext/2022/06000/Persisting,_unilateral_tinnitus_22_days_after.175.aspx

3 cases of Tinnitus following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34120553/

COVID-vaccine associated tinnitus: a review of VAERS: https://pubmed.ncbi.nlm.nih.gov/35096388/

18 cases of idiopathic sensorineural hearing loss, tinnitus, and/or vertigo following Moderna/Pfizer: https://pubmed.ncbi.nlm.nih.gov/34267103/

18 cases of idiopathic sensorineural hearing loss, tinnitus, and/or vertigo following Moderna/Pfizer: https://pubmed.ncbi.nlm.nih.gov/34267103/

Tinnitus/cochleopathy following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34297133/

3 cases of sudden sensorineural hearing loss following Pfizer and AstraZeneca: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520501/

Vestibular neuritis in a 54yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34898387

Bilateral Vocal Fold Paralysis after 3rd dose Pfizer requiring intubation and tracheostomy: https://pubmed.ncbi.nlm.nih.gov/35762144/

Ulcers of bilateral palate mucosa following Moderna in a 58yoF: https://pubmed.ncbi.nlm.nih.gov/35114426/

Lipschutz ulcers after AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34366434/

**ID:**

Persistent varicella zoster virus infection following mRNA COVID-19 vaccination was associated with the presence of encoded spike protein in the lesion: https://onlinelibrary.wiley.com/doi/10.1002/cia2.12278

Herpes Zoster following Moderna: https://pubmed.ncbi.nlm.nih.gov/34397201/

10 cases of herpes zoster following covid vaccination: https://pubmed.ncbi.nlm.nih.gov/35746994/

2 cases (80yoF, 69yoF) of herpes ophthalmicus following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34585774/

Herpes Zoster reactivation following Moderna: https://pubmed.ncbi.nlm.nih.gov/34316506/

Herpes Zoster following mRNA vaccination in a patient with ankylosing spondylitis: https://pubmed.ncbi.nlm.nih.gov/34814659/

5 cases of Herpes Zoster following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35180059/

Zoster meningitis after Pfizer vaccination in a 39yoF: https://pubmed.ncbi.nlm.nih.gov/35186672/

1 case HSV meningitis and 2 cases herpes zoster ophthalmic following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35097240/

Ramsy Hunt syndrome following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34344559/

L-lysine in herpesvirus reactivation after AstraZeneca vaccine: a minor literature review and case report: https://pubmed.ncbi.nlm.nih.gov/34962036/

A case series of Herpes Zoster following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34363717/

2 cases of herpes zoster following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34428545/

2 cases of herpes zoster in healthy young adults following vaccination: https://pubmed.ncbi.nlm.nih.gov/34363257/

3 cases of Herpes Zoster following Vaccination (Moderna and AstraZeneca): https://pubmed.ncbi.nlm.nih.gov/34293165/

3 cases of Herpes Zoster after covid vaccination in patients with chronic urticaria being treated with cyclosporine: https://pubmed.ncbi.nlm.nih.gov/34510694/

4 cases of Herpes Zoster (2 pfizer, 2 astrazeneca): https://pubmed.ncbi.nlm.nih.gov/34310754/

6 cases of Herpes Zoster following Pfizer: https://pubmed.ncbi.nlm.nih.gov/33848321/

COVID-19 vaccines and herpes infection: https://pubmed.ncbi.nlm.nih.gov/34786482

A case of varicella-zoster virus after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34390376/

Varicella zoster reactivation and mRNA vaccines as a trigger: https://pubmed.ncbi.nlm.nih.gov/34316507/

40 cases of HSV and VZV reactivation following mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/34487581/

## Autoinmune:

New-onset autoimmune phenomena post COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34957554/

American College of Rheumatology Guidance for COVID-19 vaccination: theoretical risk exists for AIIRD flare and potential risk for new onset autoimmunity: https://onlinelibrary.wiley.com/doi/10.1002/art.41877

Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk Factor of Multisystem Inflammatory Syndrome? https://www.mdpi.com/2076-393X/9/11/1353/pd

Analysis of neurologic adverse events reported in VigiBase from COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/35198288/

A Possible Role for Anti-idiotype Antibodies in SARS-CoV-2 Infection and Vaccination https://www.nejm.org/doi/10.1056/NEJMcibr211369

Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases” https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7833091/

## Síndrome inflamatorio multisistémico:

MIS, Pericarditis, and HLH in a 36yoF following Astrazeneca: https://pubmed.ncbi.nlm.nih.gov/34862234/

Multisystem inflammatory syndrome in an adult following Pfizer (MIS-V): https://pubmed.ncbi.nlm.nih.gov/34326117/

MIS in 2 adults with short interval between COVID-19 infection and subsequent vaccination: https://pubmed.ncbi.nlm.nih.gov/35320702/

Two cases of MIS-V: 12yoM and 14yoM: https://pubmed.ncbi.nlm.nih.gov/35614536/

Two cases of MIS-V: 15yoF and 17yoF: https://pubmed.ncbi.nlm.nih.gov/35275051/

MIS-V in a 16yoM 3weeks after booster vaccination: https://pubmed.ncbi.nlm.nih.gov/35617041/

MIS-V in a 21yoM following 2nd dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/35282400/

MIS resulting in reversible autoimmune cardiomyopathy in a 25yoM following 3rd dose of COVID vaccination: https://pubmed.ncbi.nlm.nih.gov/35747051/

MIS-V with erythema multiforme-like rash in a 62yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35248401/

Multisystem inflammatory syndrome in an adult following Pfizer (MIS-V): https://pubmed.ncbi.nlm.nih.gov/34326117/

MIS-V in a 22yoF following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35719439/

Multisystem inflammatory syndrome in a 12yo male following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34978781/

Multisystem inflammatory Syndrome in a 12 year old boy after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34955518/

MIS in a 12yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35062704/

3 cases of Multisystem Inflammatory Syndrome after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34034858/

Multisystem Inflammation in a 20yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/34765984/

MIS-A in a 21yoF following Moderna vaccination which was given 27 days after COVID infection: https://pubmed.ncbi.nlm.nih.gov/34954311/

MIS-A in a 37yoF 10 days post 2nd Moderna COVID vaccine and 1 month from COVID infection: https://pubmed.ncbi.nlm.nih.gov/34868588/

Multisystem inflammatory syndrome in children by covid-19 vaccination of adolescents in France: https://pubmed.ncbi.nlm.nih.gov/34928295/

Multisystem inflammatory syndrome in a COVID-19 vaccinated adolescent female with sickle cell disease: https://pubmed.ncbi.nlm.nih.gov/34955521/

Autoantibody release in children after COVID mRNA vaccination: A risk factor of multisystem inflammatory syndrome? https://pubmed.ncbi.nlm.nih.gov/34835284/

MIS in a 12yoM following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35062704/

Multisystem inflammatory syndrome following COVID-19 vaccination: ignored and underdiagnosed: https://pubmed.ncbi.nlm.nih.gov/34940858/

Postmortem investigation of fatalities following vaccination with COVID-19 vaccines: https://pubmed.ncbi.nlm.nih.gov/34591186/

Autopsy findings and causality relationship between death and covid-19 vaccination: a systematic review: https://pubmed.ncbi.nlm.nih.gov/34945172/

MIS-C in a a male adolescent after his second dose of Pfizer: https://pubmed.ncbi.nlm.nih.gov/34617315/

Multisystem inflammatory syndrome in an adult following AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/34811978/

Postvaccination MIS in an adult with no evidence of prior COVID-19 infection following AstraZeneca:https://pubmed.ncbi.nlm.nih.gov/34852213/

MIS-A in an adult woman 18 days following AstraZeneca vaccination: https://pubmed.ncbi.nlm.nih.gov/34511054/

MIS in a 16yoM following 1st dose mRNA vaccination: https://pubmed.ncbi.nlm.nih.gov/35187466/

MIS-A in 65yoM, Pfizer vaccine induced, with polyserositis detected by FDGMIS after J&J vaccine: https://pubmed.ncbi.nlm.nih.gov/35096528/

Fatal Multisystem inflammatory syndrome after 2nd dose of Pfizer:https://pubmed.ncbi.nlm.nih.gov/34586059/

## Ostetra Ginecología:

Increased menstrual bleeding in 39,000 women after vaccination: https://www.science.org/doi/10.1126/sciadv.abm7201

2 cases of adolescents with vulvar ulcers following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35104637/

Vulvar aphthous ulcer after Pfizer in a 12yoF: https://pubmed.ncbi.nlm.nih.gov/34888935/

Vulvar aphthous ulcer in a 14yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34718079/

Vulvar aphthous ulcer in a 16yoF after Pfizer: https://pubmed.ncbi.nlm.nih.gov/34706274/

3 cases of acute vulvar aphthosis following Pfixer and AstraZeneca: https://pubmed.ncbi.nlm.nih.gov/35220345/

2 cases of adolescents with vulvar ulcers following Pfizer: https://pubmed.ncbi.nlm.nih.gov/35104637/

Acute genital ulceration after Pfizer (12 and 14yo) and a 29yo after Moderna: https://pubmed.ncbi.nlm.nih.gov/35413297/

## Varios:

Signaling COVID-19 Vaccine Adverse Events: https://link.springer.com/article/10.1007/s40264-022-01186-z?fbclid=IwAR0B0IFs4zK-1FK_CcjvkYw0Qvwoq35zZvxNHmJDl3dDw0Fsf3pxH5uDPwk

SARS–CoV–2 Spike Impairs DNA Damage Repair and Inhibits V(D)J Recombination In Vitro https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8538446/

Adverse effects of the Covid-19 vaccines: the spike hypothesis https://www.cell.com/trends/molecular-medicine/fulltext/S1471-4914(22)00103-4

SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties – WITHOUT virus https://www.sciencedirect.com/science/article/pii/S0889159121006383

The BNT162b2 mRNA vaccine against SARS-COV-2 reprograms both adaptive and innate immune response:https://www.medrxiv.org/content/10.1101/2021.05.03.21256520v1?fbclid=IwAR1MV3eNa-8MZFJb_SZqAF0ycaWrMM4u5_80cL2TA7_9C2MxyJkTjdZnMjQ

Does COVID-19 RNA based vaccines put at risk of immune-mediated diseases? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833091/

Cardiovascular, neurological, and pulmonary events following COVID-19 vaccination: an analysis of European data: https://pubmed.ncbi.nlm.nih.gov/34710832/

Comparative Safety of mRNA Vaccines with 433,672 US Veterans. Supplemental Material https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2793236

Adverse events following covid-19 vaccination in South Korea from Feb to August 2021: a nationwide observational study: https://pubmed.ncbi.nlm.nih.gov/35276381/

Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after covid-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35136071/

Adverse effects of COVID mRNA vaccines: the spike hypothesis: https://pubmed.ncbi.nlm.nih.gov/35537987/

Adverse drug reactions from Pfizer and AstraZeneca in Saudi Arabia: https://pubmed.ncbi.nlm.nih.gov/35095267/

International call for vaccine adverse reaction investigation: https://www.researchgate.net/publication/351670290_SARS-CoV-2_mass_vaccination_Urgent_questions_on_vaccine_safety_that_demand_answers_from_international_health_agencies_regulatory_authorities_governments_and_vaccine_developers?fbclid=IwAR1Gwfel6khY8ObziHNTGZriwS0Gez0CCp8zjaHllCJ9lfceD2EkJdMKmYw

Severe COVID-19 Vaccine (Pfizer) Side Effects are rare in older adults yet are linked with depressive symptoms: https://pubmed.ncbi.nlm.nih.gov/34804334/

Serious adverse events following immunization with AstraZeneca in India, a single center experience: https://pubmed.ncbi.nlm.nih.gov/34804334/

Adverse events with Pfizer among Korean healthcare workers: https://pubmed.ncbi.nlm.nih.gov/34816647/

Pathophysiological changes after vaccination:https://pubmed.ncbi.nlm.nih.gov/34697287/

New-onset panic disorder following Pfizer vaccination: https://pubmed.ncbi.nlm.nih.gov/35180816/

Psychosis associated with COVID-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/35180812/

Characteristics and outcomes of adverse events after vaccination: https://pubmed.ncbi.nlm.nih.gov/34693399/

Symptomology following mRNA vaccination:https://pubmed.ncbi.nlm.nih.gov/34687733/

Pfizer and AstraZeneca post-vaccination side effects among Saudi vaccinees:https://pubmed.ncbi.nlm.nih.gov/34692740/

Prevalence of severe adverse events after AstraZeneca in Togo: https://pubmed.ncbi.nlm.nih.gov/34819146/

Immune mediate events associated with COVOD-19 disease, a review of Slovenia data: https://pubmed.ncbi.nlm.nih.gov/34740853/

Concerns for Pfizer vaccine failure to wildtype variants after Delta and vaccine induced enhanced illness, as demonstrated in a mice model: https://www.biorxiv.org/content/10.1101/2021.08.22.457114v1.full.pdf

Concerns about the lipid nanoparticle in the mRNA contributing to adverse reactions: https://www.biorxiv.org/content/10.1101/2021.03.04.430128v1.full?fbclid=IwAR2yUJH9kAb01O2PJ46AfBvQANuGiQvZd3ROs4R8qNJF6CZ4f255hDdRsSY

Covid-19 Vaccine Injuries — Preventing Inequities in Compensation https://www.nejm.org/doi/full/10.1056/NEJMp2034438

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory: https://pubmed.ncbi.nlm.nih.gov/34841223/